Patent Grant
10195409
The subject matter described herein relates generally to a method and delivery system for drug delivery using microprojections, and more specifically to applicators for applying an array of microprojections that provide multiple impacts.
Arrays of microneedles were proposed as a way of administering drugs through the skin in the 1970s, for example in U.S. Pat. No. 3,964,482. Microneedle or microstructure arrays can facilitate the passage of drugs through or into human skin and other biological membranes in circumstances where ordinary transdermal administration is inadequate. Microstructure arrays can also be used to sample fluids found in the vicinity of a biological membrane such as interstitial fluid, which is then tested for the presence of biomarkers.
In recent years it has become more feasible to manufacture microstructure arrays in a way that makes their widespread use financially feasible. U.S. Pat. No. 6,451,240 discloses some methods of manufacturing microneedle arrays. If the arrays are sufficiently inexpensive, for example, they may be marketed as disposable devices. A disposable device may be preferable to a reusable one in order to avoid the question of the integrity of the device being compromised by previous use and to avoid the potential need of resterilizing the device after each use and maintaining it in controlled storage.
In addition to cost, integrity and sterility, a further issue with microneedle arrays is bioavailability of the active agent. An intravenous injection delivers a precise quantity of an active agent to the circulation. A subcutaneous or intramuscular injection delivers a precise quantity of an active agent into the tissue, but the quantity of active agent delivered to the circulation and the rate at which active ingredient is delivered are affected by the type of surrounding tissue, circulation, and possibly other factors. When a drug is delivered orally, the resulting blood levels may exhibit substantial variation among patients due to metabolism and other factors, but minimal therapeutic levels can be assured for most patients, for example, because the rate of metabolism has an upper limit and because there is long experience with the absorption of many drugs from oral formulations. When a drug is delivered to unmodified skin by a conventional transdermal patch, the bypassing of the hepatic circulation may lessen the effect of liver metabolism on bioavailability. On the other hand, with a conventional transdermal patch, differences in skin permeability are an additional factor leading to differences in bioavailability.
Microneedles manipulate the permeability of the skin with respect to the active agent. Variability in the permeability enhancement created by different applications of the microneedles will result in variations in the rate of transfer through the skin, the amount transferred through the skin and the bioavailability. Variability of skin permeability enhancement on the application of a microneedle array can result from application on different patients. Particular concern exists, of course, if the enhancement is small in particular patient populations so that the administration of the drug will not produce a therapeutically effective dosing (e.g., adequate blood levels) in those populations. Concern may arise also if the enhancement is sometimes undesirably small in a patient, even if at other times the enhancement is as expected in that patient, depending on details of how and where the microneedle array is applied.
A typical microneedle array comprises microneedles projecting from a base of a particular thickness, which may be of any shape, for example square, rectangular, triangular, or circular. The microneedles themselves may have a variety of shapes. While an array could be pressed by hand into skin, it has also been proposed to use a variety of devices to hold the microneedle array as it is being applied or to facilitate in one way or another the process of microneedle array application to the skin or other biological membrane. Such devices may broadly be referred to as “applicators.” Applicators may for example reduce the variations in force, velocity, and skin tension that occur when a microneedle array is pressed by hand into the skin. Variations in force, velocity and skin tension can result in variations in permeability enhancement.
In some applications of microneedle arrays, they may be applied to the skin or other biological membrane in order to form microchannels and then are more or less immediately withdrawn. In other applications the microneedle array may be held in place for a longer period of time. The design of the applicator may naturally be influenced by how long the microneedles are expected to stay in place.
Applicators for microneedles comprising components which have two stable states have been described in U.S. Published Patent Application No. 2008/0183144. The existence of two stable states is a feature generally desired in an applicator because the energy difference between the two stable states can allow each use of the applicator to employ a fixed amount of energy in order to cause penetration, improving reproducibility.
One problem with prior art applicator designs is that the energy required to achieve penetration of the microneedles may result in a force to the patient's skin that is uncomfortable or painful. U.S. Pat. No. 6,743,211 describes vibrating the microneedles and/or the skin to enhance penetration. However, existing vibratory applicators are complex and expensive. They typically use a stand-alone piece of equipment, usually electronic in nature, to provide vibration. This separate, non-disposable vibratory machine is undesirable or even unobtainable in many areas. These devices are primarily used in a research setting due to their cost and complexity.
There is a need in the art for applicators and related devices suitable for use with microneedle arrays, for example, in order to assist in making the process of drug delivery more user friendly and uniform across patients and for different applications to the same patient. There is also a need for an applicator which has sufficient force to achieve desired penetration of a patient's skin with the microprojections without causing discomfort or pain.
The foregoing examples of the related art and limitations related therewith are intended to be illustrative and not exclusive. Other limitations of the related art will become apparent to those of skill in the art upon a reading of the specification and a study of the drawings.
The following aspects and embodiments thereof described and illustrated below are meant to be exemplary and illustrative, not limiting in scope.
In one aspect, an applicator for a microprojection array is provided.
In one aspect, a method of delivering a therapeutic agent to a subject, comprises (i) applying to a skin site of a subject, an applicator comprising at least one plunger element, at least one microprojection retained on a distal surface of the plunger, and an actuator; (ii) actuating the actuator to convey an external force to the at least one plunger element such that an energy required for the at least one microprojection to penetrate the skin site is delivered in multiple, discrete quanta and/or impacts.
In an embodiment, a maximum strain and/or strain rate is not exceeded by any of the multiple, discrete quanta and/or impacts. In further embodiments, there is sufficient delay between impacts to allow a strain from a previous impact to dissipate.
In an embodiment, the at least one microstructure partially penetrates the skin site from a first impact, and the method further comprises detaching the at least one microstructure from the plunger distal end.
In embodiments, the multiple, discrete quanta and/or impacts are created by any one of or a combination of methods and devices including:
(a) the plunger comprises multiple energy-mass systems or the device includes a plurality of plunger elements each with an energy-mass system, each system having a different time constant so that the energy-mass systems progressively deploy;
(b) the applicator comprises a plurality of plunger elements and an asynchronous release mechanism such that the plunger elements are released at different time periods;
(c) the applicator comprises a plurality of plunger elements each comprising a dashpot element having a different damping coefficient;
(d) the applicator comprises a plurality of plunger elements, each having a different type of spring; and
(e) the applicator further includes a vibration element.
In embodiments, each of the energy-mass systems has a progressively higher time constant such that the plunger elements impact the skin site in a defined sequence. In embodiments, the impacts are sequential. The timing of the impacts may be regular or irregular, which may depend on the time required for the strain from the prior impact to dissipate. In further embodiments, each energy-mass element includes a spring and a mass element. In additional embodiments, a delay in impact from the plunger elements may be modified by adjusting a spring constant of one or more springs in the energy-mass elements. In other embodiments a delay in impact from the plunger elements may be modified by adjusting a mass of the mass elements. In further embodiments, a cam or other mechanical feature may be used to build in delays in release in order to provide the asynchronous release. In additional embodiments, the different types of springs are selected from coiled springs, wave springs, and slotted springs. In further embodiments, an amplitude of the vibration element is controlled to limit an impact strain from one or more of the multiple, discrete quanta and/or impacts. In other embodiments, a frequency of the vibration element is controlled to limit an impact strain from one or more of the multiple, discrete quanta and/or impacts.
In another aspect, an applicator, comprises (i) at least a first plunger element comprising a first energy-mass system, the first plunger element having a first restrained position and a second extended position, the first plunger element comprising a distal end on which at least one microprojection can be retained; (ii) at least a second energy-mass system, wherein the first and second energy-mass systems each has a different time constant, and each energy-mass system has a first restrained position and a second extended position; and (iii) an actuating member that can convey an external force to at least the first plunger element to release the first plunger element from the first restrained position.
In embodiments, the applicator further includes at least one microstructure attached to a distal surface of the plunger element distal end.
In embodiments, the first and second energy-mass systems each includes a mass and an energy-storing element. In other embodiments the energy-storing elements are elastic energy elements. In further embodiments, the energy-storing elements are each selected from a compression spring, a coil spring, a wave spring, and a slotted spring. The energy-storing elements for the different energy-mass systems may be the same or different for each energy-mass system.
In embodiments, the energy-mass systems each have a time constant such that the energy-mass systems are released at the same time (simultaneously or near simultaneously) but deploy at different rates, and thus impact at different times. The applicator of any previous claim, wherein the first energy-mass system has a faster time constant than the second energy-mass system. In other embodiments, the mass of the first energy-mass system is different than the mass of the second energy-mass system. In further embodiments, the first energy-mass system has a stored energy sufficient to deploy the at least one microprojection at least partially into a subject's skin when the stored energy is released.
In embodiments, the applicator includes further energy-mass systems (third, fourth, fifth, or more) depending on the number of impacts desired. In an embodiment, the applicator includes a third energy-mass system, wherein the third energy-mass system has a different time constant than the first or second energy-mass systems. In other embodiments, the third energy-mass system has a slower time constant than the first or second energy-mass systems.
In embodiments, the applicator includes a housing where the first plunger element and actuating member are at least partially positioned in the housing. In other embodiments, the housing member includes a skin-contacting surface. In further embodiments, the skin-contacting surface further comprising an adhesive to secure the housing to a surface.
In embodiments, the at least one microprojection is a microprojection array comprising a plurality of microprojections. In other embodiments, at least some of the plurality of microprojections are dissolvable or erodible microprojections. In additional embodiments, at least some of the plurality of microprojections include at least one therapeutic agent. In yet other embodiments, the therapeutic agent is selected from a drug, a small molecule, a peptide or protein, or a vaccine. In other embodiments, at least a portion of the plurality of microprojections are detachable from the microprojection array.
In an embodiment, the first plunger element contacts a subject's skin with an energy of about 0.15-0.2 J.
In another embodiment, the applicator further includes a backing member positioned on the distal surface of the first plunger distal end, wherein the backing member comprises the at least one microprojection; the backing member being detachable from the first plunger element distal end. In other embodiments, the backing member comprises a support layer adjacent the distal surface of the first plunger element distal end and an adhesive layer, wherein the at least one microprojection is positioned distal to the adhesive layer. In additional embodiments, the at least one microprojection is a microprojection array positioned distal to the adhesive layer. In further embodiments, the adhesive layer at least partially surrounds the at least one microprojection.
In embodiments, the applicator further includes a damper positioned between at least one of the energy-storing elements and a proximal surface of the first plunger element distal end.
In another aspect, a method of delivering a therapeutic agent to a subject, comprises an applicator as described herein; actuating the actuating member to convey an external force to at least the first plunger element; releasing the first plunger element from the first restrained position to the second extended position to impact the subject's skin; and releasing the second energy-mass system from the first restrained position to the second extended position with a different time constant than the first plunger element; wherein the second energy mass system impacts a proximal surface of the first plunger distal end.
In an embodiment, the first plunger contacts the skin site of the subject with sufficient force for the at least one microprojection to at least partially penetrate the skin. In another embodiment, impact of the second energy-mass system on the first plunger element causes the at least one microprojection to penetrate the skin further upon impact.
In embodiments, the method further includes adhering the applicator to the subject's skin. In other embodiments, in the deployed position, the first plunger element has an equilibrium position such that the distal end of the plunger on which the at least one microprojection is retained is positioned below a surface of the skin. In further embodiments, the equilibrium position is about 0.03-0.2 inches below the surface of the skin of the subject.
In embodiments, the method further includes detaching a backing member such that the backing member and the at least one microprojection are retained on the subject's skin.
In embodiments, the therapeutic agent is selected from a drug, a small molecule, a peptide or protein, or a vaccine.
In another aspect, an applicator, comprises (a) a plunger element comprising at least a shaft and a distal end on which at least one microprojection can be retained; (b) at least one projection positioned on a proximal surface of the plunger distal end, the plunger having a first restrained position and a second extended position; (c) an actuating member that can convey an external force to the plunger element to release the plunger element from the first restrained position; (d) a linear energy-storing member positioned between the actuator and the plunger distal end, the linear energy-storing member having a first position and a second position, wherein the linear energy-storing member is effective to move the plunger from its first position to its second position as the linear energy-storing member moves from its first position to its second position; and (e) a torsional energy-mass system at least partially surrounding the plunger shaft and being positioned between the linear energy-storing member and the plunger distal end, wherein the torsional energy-mass system contacts the at least one projection as the torsional energy-mass system rotates about the plunger shaft.
In embodiments, the at least one projection comprises a plurality of projections spaced apart around the proximal surface of the plunger distal end.
In embodiments, the torsional energy-mass system contacts the at least one projection as the torsional energy-mass system rotates about the plunger shaft and pushes the plunger distal end downward. In further embodiments, the torsional energy-mass system includes a rod perpendicular to an axis of motion of the linear energy-storing member, wherein the rod contacts the at least one projection as the torsional energy-mass system rotates.
In embodiments, impact of the plunger distal end on a patient's skin releases the torsional spring-mass system.
In embodiments, each of the at least one protrusions are wedge shaped.
In embodiments, the energy-storing member is an elastic energy element. In other embodiments, the energy-storing elements are each selected from a compression spring, a coil spring, a wave spring, and a slotted spring. In further embodiments, the linear energy-storing member has a stored energy sufficient to deploy the at least one microprojection into a subject's skin when the stored energy is released.
In embodiments, the applicator includes a housing member at least partially housing the plunger member and actuating member. In other embodiments, the housing member includes a skin-contacting surface. In further embodiments, the skin-contacting surface further comprising an adhesive to secure the housing to a surface.
In embodiments, the at least one microprojection is a microprojection array comprising a plurality of microprojections. In other embodiments, at least some of the plurality of microprojections are dissolvable or erodible microprojections.
In embodiments, the plurality of microprojections includes at least one therapeutic agent. In further embodiments, the therapeutic agent is selected from a drug, a small molecule, a peptide or protein, or a vaccine.
In embodiments, at least a portion of the plurality of microprojections are detachable from the microprojection array.
In embodiments, the plunger element contacts a subject's skin with a force of about 0.15-0.2 J.
In embodiments, the applicator includes a backing member positioned on a bottom surface of the plunger distal end, wherein the backing member comprises the at least one microprojection; the backing member being detachable from the plunger distal end.
In embodiments, the backing member comprises a support layer adjacent the distal surface of the plunger distal end and an adhesive layer, wherein the at least one microprojection is positioned distal to the adhesive layer. In other embodiments the at least one microprojection is a microprojection array positioned distal to the adhesive layer. In further embodiments, the adhesive layer at least partially surrounds the at least one microprojection.
In embodiments, the applicator includes a damper positioned between the energy-storage devices and a proximal surface of the plunger distal end.
In another aspect, a method of delivering a therapeutic agent to a subject, comprises applying to a skin site of the subject, an applicator according to any one of the above embodiments, actuating the actuating member to convey an external force to the plunger element; releasing the plunger element from the first restrained position to the second extended position; rotating the torsional energy-mass system about the plunger shaft such that the system contacts the at least one projection on the plunger proximal surface and pushes it downward as the system rotates about the plunger shaft thereby to move the plunger distal end toward the skin site.
In embodiments, the plunger contacts the skin site of the subject in the extended position with sufficient force for the at least one microprojection to at least partially penetrate the skin. In other embodiments, rotation of the torsional energy-mass system causes the plunger to impact the patient's skin and causes the at least one microprojection to penetrate the skin further upon each impact. In further embodiments, the plunger distal end comprises a plurality of projections spaced apart around the proximal surface of the plunger distal end and rotation of the torsional energy-mass system causes the plunger to impact the patient's skin each time the system contacts one of the plurality of projections. In additional embodiments, the method includes adhering the applicator to the subject's skin.
In embodiments, in the deployed position, the plunger element has an equilibrium position such that the distal end of the plunger on which the at least one microprojection is retained is positioned below a surface of the skin. In other embodiments, the equilibrium position is about 0.03-0.2 inches below the surface of the skin of the subject.
In embodiments, the method further includes detaching a backing member such that the backing member and the at least one microprotrusion is retained on the subject's skin.
In embodiments, the therapeutic agent is selected from a drug, a small molecule, a peptide or protein, or a vaccine.
Additional embodiments of the present devices, apparatuses, methods, and the like, will be apparent from the following description, drawings, examples, and claims. As can be appreciated from the foregoing and following description, each and every feature described herein, and each and every combination of two or more of such features, is included within the scope of the present disclosure provided that the features included in such a combination are not mutually inconsistent. In addition, any feature or combination of features may be specifically excluded from any embodiment of the present invention. Additional aspects and advantages of the present devices, apparatuses, and methods are set forth in the following description and claims, particularly when considered in conjunction with the accompanying examples and drawings.
It will be appreciated that the thicknesses and shapes for the various applicators and microstructure arrays have been exaggerated in the drawings to facilitate understanding of the device. The drawings are not necessarily “to scale.”
Various aspects now will be described more fully hereinafter. Such aspects may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein; rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey its scope to those skilled in the art.
The practice of the present disclosure will employ, unless otherwise indicated, conventional methods of chemistry, biochemistry, and pharmacology, within the skill of the art. Such techniques are explained fully in the literature. See, e.g.; A. L. Lehninger, Biochemistry (Worth Publishers, Inc., current addition); Morrison and Boyd, Organic Chemistry (Allyn and Bacon, Inc., current addition); J. March, Advanced Organic Chemistry (McGraw Hill, current addition); Remington: The Science and Practice of Pharmacy, A. Gennaro, Ed., 20th Ed.; Goodman & Gilman The Pharmacological Basis of Therapeutics, J. Griffith Hardman, L. L. Limbird, A. Gilman, 10th Ed.
Where a range of values is provided, it is intended that each intervening value between the upper and lower limit of that range and any other stated or intervening value in that stated range is encompassed within the disclosure. For example, if a range of 1 μm to 8 μm is stated, it is intended that 2 μm, 3 μm, 4 μm, 5 μm, 6 μm, and 7 μm are also explicitly disclosed, as well as the range of values greater than or equal to 1 μm and the range of values less than or equal to 8 μm.
I. Definitions
As used in this specification, the singular forms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to a “polymer” includes a single polymer as well as two or more of the same or different polymers; reference to an “excipient” includes a single excipient as well as two or more of the same or different excipients, and the like.
In describing and claiming the present invention, the following terminology will be used in accordance with the definitions described below.
In discussing the applicators and arrays, the term “downward” is sometimes used to describe the direction in which microprotrusions are pressed into skin, and “upward” to describe the opposite direction. However, those of skill in the art will understand that the applicators and arrays can be used where the microprotrusions are pressed into skin at an angle to the direction of the earth's gravity, or even in a direction contrary to that of the earth's gravity. In many applicators, the energy for pressing the microprotrusions is provided primarily by an energy-storage member and so efficiency is not much affected by the orientation of the skin relative to the earth's gravity.
The terms “microprotrusion”, “microprojection”, “microstructure” or “microneedle” are used interchangeably herein to refer to elements adapted to penetrate or pierce at least a portion of the stratum corneum or other biological membranes. For example, illustrative microstructures may include, in addition to those provided herein, microblades as described in U.S. Pat. No. 6,219,574, edged microneedles as described in U.S. Pat. No. 6,652,478, and microprotrusions as described in U.S. Patent Publication No. U.S. 2008/0269685.
The term “microprotrusion array” for purposes herein is intended to denote a two-dimensional or a three-dimensional arrangement of microprotrusions, microprojections, microstructures, or microneedles. The arrangement may be regular according to a repeating geometric pattern or it may be irregular.
“Optional” or “optionally” means that the subsequently described circumstance may or may not occur, so that the description includes instances where the circumstance occurs and instances where it does not.
“Substantially” or “essentially” means nearly totally or completely, for instance, 80-85%, 80-90%, 80-95%, 85-90%, 85-95%, 90-95% or greater of some given quantity.
In this application reference is often made for convenience to “skin” as the biological membrane which the microneedles penetrate. It will be understood by persons of skill in the art that in most or all instances the same inventive principles apply to the use of microneedles to penetrate other biological membranes such as, for example, those which line the interior of the mouth or biological membranes which are exposed during surgery. In other embodiments, the inventive principles may apply to the use of microneedles for cell walls. For example, the microneedles described herein may be used to treat a condition of the skin where certain cells that present on the surface are targeted by the microneedles.
“Transdermal” refers to the delivery of an agent into and/or through the skin or for local and/or systemic therapy.
II. Microstructure Applicators
Before describing the present subject matter in detail, it is to be understood that this invention is not limited to specific materials or device structures, as such may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting.
In general, the microstructure applicators described herein provide multiple, discrete impacts with a single applicator. These applicators provide improved microstructure penetration than achieved by a single impact. Further, the applicators provide an improved sensation to the subject by providing multiple impacts with less force than required for a single impact.
Further, the energy required for penetration by the microstructures is delivered in multiple discrete quanta/impacts. A maximum strain and/or strain rate that limits sensation from the impacts to an acceptable level is not exceeded by any of the individual impacts. Thus, sensation for the subject is limited and is independent of the total energy provided by the devices herein.
Preferably, there is sufficient delay between the discrete impacts to allow the strain from the previous impact to dissipate so that the sensation from the impacts does not accumulate.
There are several ways to provide multiple discrete impacts. Suitable devices include a device with multiple energy-mass systems, described further below; provide asynchronous release of multiple plunger elements; use dashpot elements with multiple plunger elements; use different springs to provide different expansion and therefore timed impacts; and use a vibrating element.
In one embodiment, the device includes a plurality of plunger elements where release of the plunger elements is timed to provide multiple impacts. In one embodiment, a cam is used to build a delay in release into the applicator.
In another element, dashpot elements are used to create a damping of plunger elements and thus modulate the dynamics of an energy-mass system.
In a further embodiment, the plunger elements use a spring for movement within the actuator and different spring types are used to provide for timed release of the plunger elements. Suitable springs include, but are not limited to, coiled springs, wave springs, slotted springs, etc.
In another embodiment, the device uses vibration to create multiple, discrete impacts without the need to detach the microstructure array from the plunger. Preferably, the vibration element or device is associated with the actuating element. In one embodiment, the amplitude of vibration is controlled to ensure the strain is limited. In a second embodiment, the frequency is selected such that strain rates are limited and there is sufficient recovery time allowed for sensation to the subject to be limited. It will be appreciated that these embodiments may be used in combination.
In embodiments, the strain and/or strain rate may be limited and/or adjusted to a specified strain and/or rate. In embodiments, the strain and/or strain rate are limited to below a level which causes discomfort and/or pain sensation for the subject.
In an embodiment, the applicators and methods provide for a strain that is between about 0.1-100. In other embodiments, the strain is between about 0.1-5, about 0.1-10, about 0.1-15, about 0.1-20, about 0.1-25, about 0.1-30, about 0.1-40, about 0.1-50, about 0.1-60, about 0.1-70, about 0.1-75, about 0.1-80, about 0.1-90, about 0.1-95, about 0.5-100, about 0.5-10, about 0.5-15, about 0.5-20, about 0.5-25, about 0.5-30, about 0.5-40, about 0.5-50, about 0.5-60, about 0.5-70, about 0.5-75, about 0.5-80, about 0.5-90, about 0.5-95, about 0.75-100, about 0.75-10, about 0.75-15, about 0.75-20, about 0.75-25, about 0.75-30, about 0.75-40, about 0.75-50, about 0.75-60, about 0.75-70, about 0.75-75, about 0.75-80, about 0.75-90, about 0.75-95, about 1-100, about 1-5, about 1-10, about 1-15, about 1-20, about 1-25, about 1-30, about 1-40, about 1-50, about 1-60, about 1-70, about 1-75, about 1-80, about 1-90, about 1-95, about 5-100, about 5-10, about 5-15, about 5-20, about 5-25, about 5-30, about 5-40, about 5-50, about 5-60, about 5-70, about 5-75, about 5-80, about 5-90, about 5-95, about 10-100, about 10-15, about 10-20, about 10-25, about 10-30, about 10-40, about 10-50, about 10-60, about 10-70, about 10-75, about 10-80, about 10-90, about 10-95, about 20-100, about 20-25, about 20-30, about 20-40, about 20-50, about 20-60, about 20-70, about 20-75, about 20-80, about 20-90, about 20-95, about 25-100, about 25-50, about 25-75, about 40-100, about 40-50, about 40-75, about 50-100, about 50-60, about 50-70, about 50-75, about 50-80, about 50-90, about 50-95, about 60-100, about 60-70, about 60-75, about 70-100, about 70-75, about 75-100, about 80-100, about 80-90, about 90-100, or about 95-100.
In an embodiment, the applicators and methods maintain a strain rate of between about 10−1-108 s−1. In other embodiments, the strain rate for the applicators and methods is between about 10−1-101, about 10−1-102, about 10−1-105, about 10−1-106, about 10−1-106, about 101-108, about 101-102, about 101-105, about 101-106, about 101-107, about 102-108, about 102-105, about 102-106, about 102-107, about 105-108, about 105-106, or about 105-107. In other embodiments, the strain rate is between about 0.1-10 s1.
It will be appreciated that any or all of these approaches may be combined as appropriate.
In one embodiment, a microstructure assembly partially penetrates the skin with the first impact and the microstructure array detaches from the applicator or plunger.
A. Energy-Mass Applicator System
In one aspect, an applicator for delivery of a needle, microneedle, microprojection, microstructure, or arrays thereof is described herein. The applicator comprises an actuator or actuating member; a plunger element, at least a first and a second energy-mass element; and at least one needle, microneedle, microstructure, or arrays thereof capable of being retained or adhered to one of the plunger elements. The applicator operates by applying a force to the actuating member above a threshold to release the plunger elements and the energy-mass elements. The plunger and energy-mass elements provide multiple, discrete impacts with a single applicator. The applicator provides similar or even improved penetration of the microstructure(s) with less or no discomfort to the subject than is achieved with a single impact applicator.
The applicator 10 includes at least one plunger element, piston, or other elongate structure 14. The plunger element may have a central post or shaft, a proximal end or portion, and a distal end or portion. The shaft preferably extends between the distal ends or portions. It will be appreciated that the plunger may have any suitable size and/or shape. The applicator further comprises at least two energy-mass elements 16, 18, 26. In embodiments, the applicator comprises a plurality of energy-mass elements. In the embodiment as shown in
The plunger element has a first constrained or restrained position and a second deployed or extended position. Further, each of the energy-mass elements has a first constrained or restrained position and a second deployed or extended position. The plunger elements and/or energy-mass elements may be retained or held in the constrained position by any suitable means. In an embodiment, the first plunger element is restrained in the first position and the second and third energy-mass elements (or further elements) are restrained by the first plunger element. In this embodiment, when the first plunger element is released from the constrained position, the second and third energy-mass elements are also released.
In one embodiment, the plunger includes at least one energy-mass element 26 effective to move the plunger from the first position to the second position when released. The energy-storing element is typically, but not always, positioned between the structure as described below and the mass element.
In one embodiment, this type of impactor/applicator should have user sensation comparable to a single-stage applicator using the maximum energy of any one of the multiple stages. The penetration, however, should be comparable to a single-stage applicator with energy equal to the sum of each of the multiple stages.
Any suitable energy-storing element is contemplated including, but not limited to springs or elastic components. In non-limiting embodiments, the energy-storing element is an elastic storage element, a compression spring, a coil spring, a wave spring, or a slotted spring device. When the plunger is in the restrained position, the energy-storage member is restrained in a high energy position of stored energy, and when the plunger is released, the energy-storage member releases its stored energy and in so doing moves the plunger. The energy storing element is typically maintained in a constrained or restrained position between a proximal surface of the plunger or the mass element and a distal surface of the structure described below. When the plunger is released, the energy storing element is released from the constrained position and the stored energy pushes the plunger distal end or mass element away from the common structure and toward the patient's skin. The amount of energy stored by the energy storing element may be adjusted based on the application area and/or microstructure structural features. The amount of stored energy may be, for example, in the range of at least about 0.1 J to at least about 10 J, or in the range of at least about 0.25 J to at least about 1 J. In other embodiments, the stored energy is in the range of at least about 0.15-0.25 J or at least about 0.15-0.2 J. In specific, but not limiting embodiments, the stored energy is at least about 0.15 J, about 0.2 J, about 0.25 J, or about 0.3 J. It will be appreciated that the energy-storage element may have sufficient stored energy for the first plunger distal end or mass to impact skin with a force of at least about 0.25 J to at least about 1 J. In other embodiments, the stored energy is in the range of at least about 0.15-0.25 J or at least about 0.15-0.2 J. In specific, but not limiting embodiments, the stored energy is at least about 0.15 J, about 0.2 J, about 0.25 J, or about 0.3 J. It will be appreciated that the energy stored by different energy-storing members may be different. For example, the energy-storing member of the first plunger element may have a greater stored energy than each of the second or further energy-storing elements. In other embodiments, each of the energy storing elements has the same or similar amount of stored energy. Preferably, the energy storing element of the first plunger element provides a sufficient energy for the microstructure or array on the plunger distal surface to pierce a subject's skin or other membrane surface. In an embodiment, the energy storing member is selected to provide a force on the plunger sufficient to cause the plunger to travel a distance longer than the length of the plunger shaft. In other embodiments including a housing discussed below, the energy storing member is selected to provide a force on the plunger sufficient to cause the plunger to travel a sufficient distance so that at least a portion of the plunger distal end exits the housing distal end.
In other embodiments, the energy-mass systems will typically accelerate at least the first plunger element to a velocity that is effective to pierce or rupture a patient's skin with the microstructure(s). In one embodiment, the maximum velocity of the microstructure(s) upon impact with the skin is about 20 meters per second (m/s) or less, about 15 m/s or less, about 10 m/s or less, about 8 m/s, about 6 m/s, about 4 m/s, or about 2 m/s. It will be appreciated that the maximum velocity for multiple impacts may vary among the impacts.
Preferably, the energy-mass elements or systems each have a different time constant such that the energy-mass elements deploy and/or impact the subject's skin at different times. In an embodiment, the first energy-mass element, associated with the plunger, has the fastest time constant such that the plunger impacts the subject's skin first based on the release of the first-energy mass system. In this embodiment, the plunger first impacts the skin with sufficient force for the microstructure(s) to rupture the skin or membrane surface and impacts from the second and/or further energy-mass elements cause increased penetration by the microstructure(s). Typically, the energy-mass systems are held by the plunger in a compressed state in decreasing order of time constant. Upon activation, the plunger and associated first energy-mass system moves fastest and separates from the other energy-mass systems. Each subsequent energy-mass system separates from the slower system behind it. The plunger impacts the subject's skin first based on release of the first energy-mass system, followed by impacts in order by each subsequent energy-mass system. Appropriate selection of energy-storing elements and masses can provide the desired time delay between impacts and total force.
As seen in
Increasing the number of impacts allows each individual impact to deliver less energy or force while achieving sufficient or desired penetration of the microstructure(s). Reducing the individual impact force of the plunger devices lowers the sensation caused by the applicator and allows for a reduction in sensation to the subject for the same microstructure penetration. Reducing the individual impact force also allows for an increase in penetration achieved with the same force.
In one embodiment, each of the plunger elements and/or energy-mass systems are attached, adhered, or otherwise connected to a common support or structure 12 that provides support to the plunger and/or energy-mass elements. The plunger elements and/or energy-mass elements may be retained by or secured to the structure by any suitable manner including, but not limited to, a mechanical feature such as a locking system, one or more fasteners, and/or an adhesive. In one embodiment, the structure is a plate. The structure may be any suitable size or shape to accommodate the plunger elements and/or systems. Where the apparatus includes a housing as described further below, the structure is preferably sized to fit within the housing. The structure may be flexible, rigid or substantially rigid. Preferably, the sufficient has sufficient mechanical strength and/or is sufficiently rigid to constrain, along with the plunger element, the energy-mass elements 16, 18, 26 as described more fully below.
As the actuator 60 is moved (e.g. from a first position to a second position), the actuator releases at least the plunger and/or first energy-mass element. It will be appreciated that the actuating member may have any shape or configuration that is suitable to allow the actuating member to push, move, or rotate to release at least the plunger and/or energy-mass element.
Pressure may be applied to move the actuating member from a first position to a second position by any suitable means including manual or mechanical. Where the pressure is manually applied, the actuating member has an external surface that is suitable for contact by a user or otherwise includes structure that allows a user to apply the appropriate pressure to the actuating member. In non-limiting embodiments, a force of at least about 0.5-10 lb is applied to the actuating member.
The bottom surface 24 of the plunger 14 further includes at least one needle, at least one microprojection, a microprojection array, a passive transdermal patch, or other delivery device for transdermal administration of one or more therapeutic agents. In an exemplary embodiment, at least one microprojection or a microprojection array is affixed, attached, adhered to, or integral with the bottom surface 24 of the plunger. In one embodiment, the delivery device is removably attached to the plunger distal surface. General features for microprojection arrays are described, for example, in U.S. Publication Nos. 2008/0269685, 2011/0276028, and U.S. Pat. Nos. 7,416,541, 7,578,954, 7,108,681, each of which are incorporated herein by reference. In embodiments, the microprojection is a hypodermic needle or a trocar. In further embodiments, the microprojection array comprises a plurality of microprojections, at least some of which are dissolvable or erodible microprojections. In further embodiments, at least some of the microprojections include at least one active agent, therapeutic agent, drug or other substance to be administered transdermally. Further, at least a portion of the microprojections may be detachable from the microprojection array. Detachable microprojection arrays are described in U.S. patent application No. 61/745,513, which is incorporated herein by reference.
In one non-limiting embodiment, the microprojection array or other delivery device is affixed or attached to the plunger distal end using an adhesive. Suitable adhesives include, but are not limited to, acrylic adhesives, acrylate adhesives, pressure sensitive adhesives, double-sided adhesive tape, double sided adhesive coated nonwoven or porous film, and UV curable adhesives. It will be appreciated that any medical device adhesive known in the art would be suitable. In another embodiment, at least a portion of the microstructure array or other delivery device is integral with at least a portion of the first plunger distal end.
The sizes of the microneedles and other protrusions for use with this invention will be a function of the manufacturing technology and of the precise application. In general, however, microneedles and other microprotrusions used in practice may be expected to have a length of about 20 to about 1000 microns, more preferably from about 50 to about 750 microns and most preferably from about 100 to about 500 microns. Often it will be desired that the microprotrusions will be long enough to penetrate at least partially through the stratum corneum layer of skin at some suitable point of application on the human body, for example the thigh, hip, arm, or torso.
The common structure and plunger may be formed of any suitable material. In one non-limiting embodiment, the common structure and plunger elements are at least partially formed of a material having an elastic modulus of between about 0.5-500 KSI. In an embodiment, at least one of the common structure and/or the plunger elements are formed of a metal including, but not limited to stainless steel, carbon steel, titanium, and alloys thereof.
As noted above, the applicator includes at least one energy-mass element or structure 16, 18, 26 positioned at least partially between a lower surface of the common structure and the distal end of the plunger element. As noted above, each of the energy-mass structures includes an energy-storing element or energy-storage member and at least one mass. A skilled artisan will appreciate the wide variety of energy-storing elements that would be suitable for use, and some examples are illustrated in U.S. Patent Publication No. 2011/0276027, which is incorporated herein by reference in its entirety. It is to be understood that other similar shapes, including but not limited to other axisymmetric shapes, may be used to create an energy-storing element. Further, non-symmetric shapes may be used to create an energy-storing element. It is also to be understood that the energy-storing element may comprise a plurality of individual energy-storing elements that may or may not be identical in size, shape, and material. The use of a plurality of individual energy-storage members may be useful to allow alteration of plunger velocity, energy, activation force, or other performance characteristics in ways that may not be achievable or different than with a single energy-storing element.
The material from which the energy-storing element is manufactured is variable, and a skilled artisan will appreciate that it is selected based on the several design considerations, including storage life and desired application force, which of course will also depend on the configuration of the member. Exemplary materials include metals, alloys, plastics, and specific examples include stainless steel and thermoplastics.
The velocity of the microprojection array or other delivery device at the time of contact with skin may be adjusted, for example, by varying the amount of stored energy in the energy-storing element and/or by changing the mass. In an embodiment, the mass in or of the plunger is varied or adjusted to adjust the velocity of the plunger. Varying the stored energy is done, for example, by controlling the energy-storing element's geometric design and the properties of the material(s) out of which the energy-storing element is made. The energy-storing element may have a compressed form in which the degree of compression (e.g., in one spatial direction) controls the amount of energy stored.
When the energy storing element is stored in a compressed form, a variety of mechanisms external to the element, but forming part of the applicator, may be employed to release the compression and allow the element to uncompress and therefore release some or all of its energy.
The applicator may further include an outer housing 28 at least partially surrounding or enclosing at least the plunger and/or energy-mass elements. Preferably at least part of the actuating member is accessible from the housing so that the user can apply pressure to the actuating member. It will be appreciated that at least a portion of the plunger extends beyond a distal end of the housing when released from its constrained or restrained position and/or at equilibrium so that the microprojection array or other delivery device is able to contact skin. It will also be appreciated that only a portion of the microstructures themselves need to extend beyond the housing distal end in order to penetrate skin. The distal end of the housing may include a skin contacting area or member 62 that is placed against a subject or patient's skin. The skin contacting area may be an annular ring positioned around an opening for the microprojection array or other delivery device. The skin contacting area may further include an adhesive for adhering the housing to the skin. The adhesive may be applied at least partially on the annular skin contacting area. In embodiments, the housing includes a surface on which an adhesive is or can be applied to secure the housing to a second surface. It will be appreciated that the skin contacting area may surround all or a portion of an opening for the microstructure array or other delivery device attached to the plunger distal end to pass through.
Applicators contemplated herein will commonly have at least two states or configurations. In the first state or configuration, the plunger is retained in a restrained or constrained position. In the first state or configuration, the energy-storing element is restrained between the common structure element and one of the plunger or an energy-mass element in a high energy position. This is typically expected to be the state of the applicator following manufacturing and during shipping and storage. When the plunger is released, the energy-storing element is released from the constrained state and releases all or a part of the stored energy. In this second state or configuration, which is arrived at by operating the actuating member or element, the microprojection array or other delivery device projects outward from the applicator.
The materials from which the applicator components are manufactured can be selected from a wide variety known to a skilled artisan. For example, a filled polymer material is suitable for manufacture of at least the outer cover or housing and/or the actuating member. A skilled artisan will understand the various material properties to be considered when selecting a suitable material for each component part.
B. Linear Energy-Mass and Torsional Energy-Mass Applicator
In another aspect, an applicator for delivery of a needle, microneedle, microprojection, microstructure, arrays thereof, or other delivery device is described herein. The applicator comprises an actuator or actuating member, at least one plunger or piston, a linear energy-mass system, and a torsional energy-mass system. The applicator operates by applying a force to the actuating member above a threshold to release the plunger.
Both the linear energy-mass system and the torsional energy-mass system are initially held in a compressed state. The linear energy-mass system and the torsional energy-mass system may be retained in the compressed state by any suitable means. The plunger and/or linear energy-mass system is released by action of an actuator, not shown, allowing the plunger distal end 36 to impact a subject's skin. The torsional energy-mass system is released and the attached rod or projection spins, rotates, or moves along an arcuate path around at least a portion of the plunger shaft 46. The rod contacts at least one of the projections(s) on the plunger distal end and the plunger distal end is pushed away from the rod providing a force in the axis of motion of the plunger toward the skin. The rod may be any suitable shape or length suitable to interact with the projections. In one embodiment, the torsional energy-mass system is released from its compressed state by impact of the plunger on the subject's skin.
In an embodiment, the plunger, piston or other elongate structure 30 has a central post or shaft 46 with a proximal end or portion and a distal end or portion 36. The shaft preferably extends at least partially between the proximal and distal ends or portions. It will be appreciated that the plunger may have any suitable shape or size. As shown at least in
The plunger distal end further comprises at least one projection positioned on the proximal surface of the distal end. In embodiments, at least about 1-6 projections are positioned on the plunger distal end. In other embodiments, at least about 1-5, about 1-4, about 1-3, about 1-2, about 2-6, about 2-5, about 2-4, about 2-3, about 3-6, about 3-5, about 3-4, about 4-6, about 4-5, about 5-6 or more projections are positioned on the plunger distal end. In specific, but not limiting embodiments, at least about 1, 2, 3, 4, 5, or 6 projections are positioned on the plunger distal end. It will be appreciated that any number of projections corresponding to the number of impacts desired may be included on the plunger distal end. The projections may be any suitable size or shape as required to move the plunger distal end a suitable or desired distance. In the embodiment, the projections are wedge or ramp-shaped. Preferably, the projections are shaped such that the rod may travel at least partially over the projection in order to move the plunger distal end. In one embodiment, at least some of the projections have a ramp or incline for interaction with the rod. The projections may be integral with or otherwise attached to the plunger distal end. Where the projections are attached to the plunger distal end, they may be attached or affixed by any suitable means including, but not limited to mechanical means and/or an adhesive. The projections may be formed of any suitable material including, but not limited to, polymers and metals. The projections may be formed of the same or different materials as the plunger.
As seen in
The applicator further includes a torsional energy-mass system comprising a torsional energy-storing element 40 and a rod or other projection 42. The torsional energy-storing element is initially held in a first constrained or restrained position. The torsional energy-storing element is released by the actuator, by release of the plunger, or other means and the rod moves in an arcuate path around at least a portion of the plunger. As the rod moves, it contacts the projections positioned on the plunger distal end. The rod moves at least partially over the projections and moves the plunger toward the patient's skin causing the plunger distal end to impact the skin one or more additional times. It will be appreciated that the impact depth is determined by the projection height and the impact duration is determined by the length of the projection. One skilled in the art may vary the size and shape of the projection in order to vary the impact dynamics including depth and duration. It will further be appreciated that the timing of the multiple impacts may be determined or controlled by the spacing between the projections and/or the speed of movement of the torsional energy-mass system.
The present embodiment may further include an outer housing 28 at least partially surrounding or enclosing the applicator. The discussion of a housing above is relevant to and included herein. Preferably at least part of the actuator is accessible or extends beyond the proximal end of the housing so that the user can apply pressure to the actuator. In another embodiment, the housing includes an actuator contacting area or element where the user applies pressure to the housing at the area or to the element that is transferred to the actuator proximal end. In another embodiment, the housing includes an opening 48 at the proximal end for a user to access the actuator. The actuator proximal end may extend at least partially through the opening in the housing or the opening may be dimensioned so that a user may access the proximal end of the actuator through the opening.
As with the above embodiment, applicators contemplated herein will commonly have at least two states or configurations. In the first state or configuration, the proximal end of the plunger is in its first retained or constrained position. In this first state or configuration, the linear energy-storing element and torsional energy-storing system are restrained in a high energy position. This is typically expected to be the state of the applicator following manufacturing and during shipping and storage. When the plunger moves from its first position to a second extended or deployed position, the linear energy-storing element is released from the constrained state and releases all or a part of the stored energy. In this second state or configuration of the linear energy storing element, which is arrived at by pressing or otherwise operating the actuating element, the microprojection array projects modestly outward from the applicator.
The applicators described in each of the embodiments described above can optionally include a safety mechanism or latch to prevent unintended actuation of the applicator and consequential deployment of the microneedle array. Various embodiments of a safety mechanism are described in U.S. Patent Publication No. 2011/0276027, which is incorporated herein in its entirety.
One problem with some prior applicators is the plunger is not deployed with sufficient energy or the plunger may bounce after contacting the skin or the skin may move away due to the impact. The skin may thus become separated from the microprotrusion array after the initial impact. Without a retaining force, the skin may separate at the end of the plunger's travel, continuing its motion as the plunger moves at a slower rate. While the microprotrusion array may later return to contact the skin as the plunger bounces, the individual microprotrusions will no longer be aligned with the holes created during the initial impact of the array with the skin and the plunger may not have sufficient energy to create new holes with the microprotrusions. Alternatively, some prior applicators suffer from the excessive application of force or displacement of the plunger. Excessive displacement or impact force of the plunger into the skin can cause uncomfortable sensations and/or pulling of the skin. Additionally, excessive compression of the skin can reduce fluid flow through the tissues surrounding the microprotrusion array, which slows dissolution of the therapeutic agent from the microprotrusions and the subsequent transport into the subject's system. Both of these problems may lead to the degradation of the drug product and/or improper or incomplete delivery of the therapeutic agent.
The proper contact of the microprotrusions with the skin may be achieved by adjusting the final equilibrium position of the plunger for any of the embodiments herein. In embodiments, the displacement of the plunger distal end is 0.03-0.2″ below the surface of the subject's skin at equilibrium. In embodiments, the final displacement of the plunger of at least 0.030″ as measured at plunger equilibrium in free air is desired. The “final displacement” refers to the extension of the plunger distal surface beyond the surface of the skin. This final displacement or the equilibrium position is determined by the length of the plunger and/or the equilibrium position of the linear energy-storage member. In other embodiments, a final displacement is approximately 0.2″. In a specific embodiment, the final displacement is 0.2″ using a spring with 54 lb/in and a plunger having a diameter of approximately 0.6″. In an embodiment, the length of the plunger shaft is selected such that it extends beyond the distal most end of the housing at equilibrium. In another embodiment, the housing distal end includes a skin contacting surface and the length of the plunger shaft is selected such that the plunger extends beyond the skin contacting surface. In yet another embodiment, the plunger distal end extends below the skin surface at equilibrium. It will be appreciated the final displacement is dependent on the force required to depress the plunger from an extended state to flush with the housing. In an embodiment, the plunger travels a distance longer than the length of the plunger shaft. It will be appreciated that the length of the plunger shaft and/or the energy storing element may be selected to provide a force on the plunger that causes the plunger to travel a distance longer than the length of the shaft.
When the microprojections are dissolvable or erodible, a further advantage of an extended plunger equilibrium position is that the continued application of force allows the dissolvable microprojections to penetrate deeper into the skin as the microprojections dissolve. The biased force pressing the microprojections into the skin to the extended equilibrium position may further cause the microprojections to penetrate deeper into the skin as the distal tips dissolve.
Without being limited as to theory, maintaining pressure on the microprotrusions at equilibrium keeps the protrusion distal ends inserted in the skin. As the microprotrusions dissolve, the continued pressure pushes the protrusions deeper into the skin until the protrusions substantially or completely dissolve.
One problem with actuators using an energy-storing element such as a spring or elastic element is that the energy storage element may exert forces on one or more components of the applicators, leading to dimensional distortion and/or creep over an extended period of time. These effects are undesirable as they lead to variations in the applicator geometry and a loss in the stored elastic energy over time. In one embodiment, at least the upper retaining component or member and the plunger are formed of materials that do not exhibit creep. In one embodiment, at least the upper retaining component and plunger are formed from a metal. Exemplary metals include, but are not limited to stainless steel, carbon steel, titanium, and alloys thereof. In another embodiment, at least the upper retaining component and plunger are formed from a plastic or polymer that does not exhibit creep and/or dimensional distortion at a given stress level. In this embodiment, all of the mechanical load from the energy storage element is borne by parts formed from materials which are not subject to dimensional distortion and creep over time. Reducing the dimensional distortion and creep leads to maintaining the same stored elastic energy for an extended period of time. Maintaining the same stored elastic energy over a period of time is important for having an extended shelf life of at least preferably 6 months, more preferably 12 months, and most preferably 24 months. In further embodiments, the same stored elastic energy is maintained over a shelf life of at least about 1-10 years. In specific, but not limiting embodiments, the same stored elastic energy is maintained over a shelf life of at least about 1 year, about 2 years, about 3 years, about 4 years, about 5 years, or about 10 years or longer.
Another issue or problem with current microstructure or microneedle arrays arises with extended use or wear of the applicators. Wearing a potentially bulky applicator for an extended period of time is inconvenient during normal activities or exercising. Another potential problem is that the microneedle arrays may bounce off the skin and cause poor drug delivery. Furthermore, another potential problem is the microneedle array may pull out of the skin after impact into the skin also causing poor drug delivery. In some embodiments of each of the applicators described herein, it is desirable for the microstructure array or other delivery device to be removable from the applicator. This embodiment provides for a low profile and/or more comfortable delivery device that can be worn for longer or extended periods of time.
In one embodiment, any or all of the present applicators may include a backing assembly that is removable from the applicator. In one embodiment, a backing assembly may include a support layer, a microstructure array or other delivery device, and an adhesive positioned at least partially around the microstructure array or delivery device. In one embodiment, the adhesive is positioned as a ring around the microstructure array. The backing assembly is initially attached or placed in close proximity to the plunger or the applicator. Preferably, the backing assembly is attached or affixed to the distal surface of the plunger. Upon activation of the applicator, the plunger is released which deploys or forces the microstructures into the skin. The backing assembly with the adhesive ring at least partially adheres to the skin, allowing the applicator to detach from the skin with the microstructures of the array being deployed at least partially in the subject's skin. Another advantage of a backing assembly is that the microstructures are prevented from pulling out of the skin as the skin tissue relaxes for extended wear durations (e.g. ≤5 minutes). Additionally, this configuration prevents microstructures from pulling out due to the plunger bouncing off the skin after impact. The backing assembly preferably detaches from the plunger immediately after impact, and the adhesive ring on the backing assembly holds the microstructure array onto the skin. The plunger bounces upward and separates from the backing assembly or the backing assembly separates from the plunger when the applicator is removed. The backing assembly with the microstructure array stays on the skin. Any suitable adhesive for adhering the backing assembly may be used including those described with reference to the skin contacting area. In an embodiment, the adhesive has sufficient adhesion to the skin to retain the microstructure array on the subject's skin when the plunger bounces away from the skin or when the applicator is removed from the subject's skin. The support layer may be formed of any suitable material including, but not limited to, polymers and metals. In an embodiment, at least the areas of the support that contact the subject's skin are biocompatible. The support layer may be rigid, semi-rigid or flexible. In one embodiment, the support layer is flexible enough to conform to the skin application site. In an exemplary embodiment, the applicator with the plunger retained by the blocking member is first placed against a subject's skin. The backing assembly is positioned on the distalmost surface of the plunger distal end. The applicator is actuated and the blocking member releases the plunger, which is deployed downward toward the patient's skin. The microstructure array on the distal end of the plunger is deployed or driven such that at least a portion of the microstructures in the array at least partially pierce or penetrate the subject's skin. The plunger bounces or otherwise moves vertically away from the skin and the backing assembly detaches from the plunger to remain on the subject's skin.
In one embodiment, any or all of the applicators described herein may include a damper to dampen the bounce, upward or vertical motion away from a subject. The plunger damper changes the system dynamics from under-damped to critically or over-damped. In non-limiting embodiments, a foam, friction material, or viscous material is placed in mechanical communication with the plunger and the energy-storing element to act as a plunger damper. The plunger damper's function is to provide an energy loss to minimize plunger bounce (vertical upward motion) after the applicator is activated and the plunger strikes the skin. In one embodiment, the damper is positioned between the linear energy-storing device or other energy-storing device and the plunger distal end. When the plunger is released from its first position, the plunger deploys and the damper expands to at least partially fill any open space between the energy-storing device and the plunger distal end.
It will be appreciated that elements and/or embodiments described above with reference to one applicator embodiment are applicable to all applicator embodiments described. Discussion of common elements between the embodiments is intended to apply to all embodiments. In particular, but without limitation, discussion of the actuating member, plunger, delivery devices, energy-storage elements, and housing with reference to one embodiment is intended to also apply to other embodiments.
III. Methods Of Use
In another aspect, a method for administering an active agent or therapeutic agent to a subject is provided. Preferably, the active or therapeutic agent is administered dermally, transdermally, mucosally, and/or transmucosally. The method comprises providing a microprojection array or other delivery device in conjunction with any one of the applicators described herein, the microprojection array or delivery device comprising at least one active agent. Preferably, the microprojection array or other delivery device is configured to deliver at least one therapeutic agent. The agent may be coated on at least a portion of the microprojections and/or contained within at least a portion of the microstructures. The agent is delivered dermally, transdermally, mucosally, or transmucosally by actuation of the applicator, to deploy the microprojection array into contact with the skin, or more generally a membrane or body surface, of a subject. The active agent to be administered can be one or more of any of the active agents known in the art, and include the broad classes of compounds such as, by way of illustration and not limitation: analeptic agents; analgesic agents; antiarthritic agents; anticancer agents, including antineoplastic drugs; anticholinergics; anticonvulsants; antidepressants; antidiabetic agents; antidiarrheals; antihelminthics; antihistamines; antihyperlipidemic agents; antihypertensive agents; anti-infective agents such as antibiotics, antifungal agents, antiviral agents and bacteriostatic and bactericidal compounds; antiinflammatory agents; antimigraine preparations; antinauseants; antiparkinsonism drugs; antipruritics; antipsychotics; antipyretics; antispasmodics; antitubercular agents; antiulcer agents; anxiolytics; appetite suppressants; attention deficit disorder and attention deficit hyperactivity disorder drugs; cardiovascular preparations including calcium channel blockers, antianginal agents, central nervous system agents, beta-blockers and antiarrhythmic agents; caustic agents; central nervous system stimulants; cough and cold preparations, including decongestants; cytokines; diuretics; genetic materials; herbal remedies; hormonolytics; hypnotics; hypoglycemic agents; immunosuppressive agents; keratolytic agents; leukotriene inhibitors; mitotic inhibitors; muscle relaxants; narcotic antagonists; nicotine; nutritional agents, such as vitamins, essential amino acids and fatty acids; ophthalmic drugs such as antiglaucoma agents; pain relieving agents such as anesthetic agents; parasympatholytics; peptide drugs; proteolytic enzymes; psychostimulants; respiratory drugs, including antiasthmatic agents; sedatives; steroids, including progestogens, estrogens, corticosteroids, androgens and anabolic agents; smoking cessation agents; sympathomimetics; tissue-healing enhancing agents; tranquilizers; vasodilators including general coronary, peripheral and cerebral; vessicants; and combinations thereof. In embodiments the therapeutic agent is a protein or a peptide. In another embodiment, the agent is a vaccine.
Non-limiting examples of peptides and proteins which may be used with microprotrusion arrays include, but are not limited to parathyroid hormone (PTH), oxytocin, vasopressin, adrenocorticotropic hormone (ACTH), epidermal growth factor (EGF), prolactin, luteinizing hormone, follicle stimulating hormone, luliberin or luteinizing hormone releasing hormone (LHRH), insulin, somatostatin, glucagon, interferon, gastrin, tetragastrin, pentagastrin, urogastrone, secretin, calcitonin, enkephalins, endorphins, kyotorphin, taftsin, thymopoietin, thymosin, thymostimulin, thymic humoral factor, serum thymic factor, tumor necrosis factor, colony stimulating factors, motilin, bombesin, dinorphin, neurotensin, cerulein, bradykinin, urokinase, kallikrein, substance P analogues and antagonists, angiotensin II, nerve growth factor, blood coagulation factors VII and IX, lysozyme chloride, renin, bradykinin, tyrocidin, gramicidines, growth hormones, melanocyte stimulating hormone, thyroid hormone releasing hormone, thyroid stimulating hormone, pancreozymin, cholecystokinin, human placental lactogen, human chorionic gonadotropin, protein synthesis stimulating peptide, gastric inhibitory peptide, vasoactive intestinal peptide, platelet derived growth factor, growth hormone releasing factor, bone morphogenic protein, and synthetic analogues and modifications and pharmacologically active fragments thereof. Peptidyl drugs also include synthetic analogs of LHRH, e.g., buserelin, deslorelin, fertirelin, goserelin, histrelin, leuprolide (leuprorelin), lutrelin, nafarelin, tryptorelin, and pharmacologically active salts thereof. Administration of oligonucleotides is also contemplated, and includes DNA and RNA, other naturally occurring oligonucleotides, unnatural oligonucleotides, and any combinations and/or fragments thereof. Therapeutic antibodies include Orthoclone OKT3 (muromonab CD3), ReoPro (abciximab), Rituxan (rituximab), Zenapax (daclizumab), Remicade (infliximab), Simulect (basiliximab), Synagis (palivizumab), Herceptin (trastuzumab), Mylotarg (gemtuzumab ozogamicin), CroFab, DigiFab, Campath (alemtuzumab), and Zevalin (ibritumomab tiuxetan).
In other embodiments, at least a portion of the distal layer comprises an agent suitable for use as a prophylactic and/or therapeutic vaccine. In an embodiment, the vaccine comprises an antigen epitope conjugated on or to a carrier protein. It will be appreciated that vaccines may be formulated with our without an adjuvant. Suitable vaccines include, but are not limited to, vaccines for use against anthrax, diphtheria/tetanus/pertussis, hepatitis A, hepatitis B, Haemophilus influenzae type b, human papillomavirus, influenza, Japanese encephalitis, measles/mumps/rubella, meningococcal diseases (e.g., meningococcal polysaccharide vaccine and meningococcal conjugate vaccine), pneumococcal diseases (e.g., pneumococcal polysaccharide vaccine and meningococcal conjugate vaccine), polio, rabies, rotavirus, shingles, smallpox, tetanus/diphtheria, tetanus/diphtheria/pertussis, typhoid, varicella, and yellow fever.
In another embodiment, at least a portion of the distal layer comprises an agent suitable for veterinary uses. Such uses include, but are not limited to, therapeutic and diagnostic veterinary uses.
As dosage requirements increase, the penetrated volume of microstructure arrays (MSA) also increases to accommodate the increased dose. The energy required to penetrate the increased volume also increases as a consequence. Increased energy for delivery of a MSA can cause increased, higher or undesirable sensations to the patient or even pain. Generally, an applicator is placed in contact with the skin such that a skin contacting surface directly contacts the external skin surface and, optionally, is adhered or affixed to the skin. A MSA is applied to the skin using a velocity that is at least or greater than a minimum velocity required for the microstructures to rupture or pierce the skin surface. With the MSA remaining in the skin, the MSA is impacted multiple, or at least one, times with a lower force. Since the MSA has already ruptured the skin surface, there is no minimum energy requirement for subsequent impacts. The MSA is impacted multiple times or until the sum of the energy of impacts is greater than or equal to the energy requirement for the MSA to penetrate a desired amount or volume. This approach spreads the energy required to achieve a desired volume penetration over time, which reduces the strain rate and keeps the strain small by keeping the energy quanta small.
In a first aspect of operation, an applicator comprising a plurality of energy-mass elements is placed in contact with a subject's skin such that a skin contacting surface of the applicator directly contacts the external skin surface (stratum corneum) and, optionally, is adhered to skin by means of adhesive disposed on the skin contacting surface. The plunger and each of the energy-mass elements are in a first, constrained state or position and are movable to a second extended or unrestrained state or configuration. Each of the energy-mass elements has a different time constant. The actuating member is pressed downward or otherwise moved causing release of the plunger from its first position. Release of the plunger from its first position also releases the energy-mass elements allowing the energy-storing elements to travel from the restrained or compressed position to an extended position. The plunger distal end is moved initially by the first energy-mass element and a microarray in contact with the plunger distal end comes forcibly into contact with skin. The second energy-mass element contacts at least a portion of the plunger according to its time constant. Contact of the second energy-mass element moves the plunger in a direction toward the subject's skin resulting in multiple impacts. The timing of the impacts may be determined or controlled by adjusting the time constant of the energy-mass elements. In one embodiment, the plunger after release has an equilibrium position such that the distal end of the plunger on which the microprotrusion array is affixed is positioned below a surface of the skin.
In a second aspect of operation, an applicator comprising a linear energy-mass element, a torsional energy-mass element, and a plunger is placed in contact with the skin such that a skin contacting surface of the applicator directly contacts the external skin surface (stratum corneum) and, optionally, is adhered to skin by means of adhesive disposed on the skin contacting surface. The plunger and each of the energy-mass elements are in a first, constrained state or position and are movable to a second extended or unrestrained state or configuration. The actuating member is pressed downward or otherwise moved causing release of the plunger from its first position. Release of the plunger from its first position also releases the linear energy-mass element allowing the linear energy-storing element to travel from the restrained or compressed position to an extended position. The plunger distal end is moved by the linear energy-mass element and a microarray in contact with the plunger distal end comes forcibly into contact with skin. The torsional energy-mass element is released and the torsional energy-storing element moves in an arcuate direction around at least a portion of the plunger shaft. In one embodiment, the torsional energy storage element is released upon initial contact or impact of the plunger distal end with the subject's skin. A rod travels perpendicular to the linear energy-mass axis of motion and around at least a portion of the plunger shaft and contacts at least one or more projections formed on or attached to the proximal surface of the plunger distal surface. Contact of the rod with each of the projections moves the plunger in a direction toward the subject's skin resulting in multiple impacts. The timing of the impacts may be determined or controlled by adjusting the spacing and shape of the projections. In one embodiment, the plunger after release has an equilibrium position such that the distal end of the plunger on which the microprotrusion array is affixed is positioned below a surface of the skin.
IV. Examples
The following examples are illustrative in nature and are in no way intended to be limiting. Efforts have been made to ensure accuracy with respect to numbers (e.g., amounts, temperature, etc.) but some errors and deviations should be accounted for. Unless indicated otherwise, parts are parts by weight, temperature is in ° C. and pressure is at or near atmospheric.
A standard applicator comprising a microstructure array is applied to a subject's skin and the skin was impacted 1, 2, or 3 times with an energy quanta of 0.2 J. Multiple impacts increase the penetrated volume.
applying to a skin site of a subject, an applicator comprising at least one plunger element, at least one microprojection retained on a distal surface of the plunger, and an actuator;
actuating the actuator to convey an external force to the at least one plunger element such that an energy required for the at least one microprojection to penetrate the skin site is delivered in multiple, discrete quanta and/or impacts.
detaching the at least one microstructure from the plunger distal end.
(a) the plunger comprises multiple energy-mass systems, each system having a different time constant;
(b) the applicator comprises a plurality of plunger elements and an asynchronous release mechanism such that the plunger elements are released at different time periods;
(c) the applicator comprises a plurality of plunger elements each comprising a dashpot element having a different damping coefficient;
(d) the applicator comprises a plurality of plunger elements, each having a different type of spring; and
(e) the applicator further includes a vibration element.
at least a first plunger element comprising a first energy-mass system, the first plunger element having a first restrained position and a second extended position, the first plunger element comprising a distal end on which at least one microprojection can be retained;
at least a second energy-mass system, wherein the first and second energy-mass systems each has a different time constant, and each energy-mass system has a first restrained position and a second extended position; and
an actuating member that can convey an external force to at least the first plunger element to release the first plunger element from the first restrained position.
a backing member positioned on the distal surface of the first plunger distal end, wherein the backing member comprises the at least one microprojection;
the backing member being detachable from the first plunger element distal end.
a damper positioned between at least one of the energy-storing elements and a proximal surface of the first plunger element distal end.
applying to a skin site of the subject, an applicator according to any one of the combined or separate embodiments 1-37;
actuating the actuating member to convey an external force to at least the first plunger element;
releasing the first plunger element from the first restrained position to the second extended position to impact the subject's skin;
releasing the second energy-mass system from the first restrained position to the second extended position with a different time constant than the first plunger element;
wherein the second energy mass system impacts a proximal surface of the first plunger distal end.
adhering the applicator to the subject's skin.
detaching a backing member such that the backing member and the at least one microprojection are retained on the subject's skin.
a plunger element comprising at least a shaft and a distal end on which at least one microprojection can be retained;
at least one projection positioned on a proximal surface of the plunger distal end, the plunger having a first restrained position and a second extended position;
an actuating member that can convey an external force to the plunger element to release the plunger element from the first restrained position;
a linear energy-storing member positioned between the actuator and the plunger distal end, the linear energy-storing member having a first position and a second position, wherein the linear energy-storing member is effective to move the plunger from its first position to its second position as the linear energy-storing member moves from its first position to its second position; and
a torsional energy-mass system at least partially surrounding the plunger shaft and being positioned between the linear energy-storing member and the plunger distal end, wherein the torsional energy-mass system contacts the at least one projection as the torsional energy-mass system rotates about the plunger shaft.
a backing member positioned on a bottom surface of the plunger distal end, wherein the backing member comprises the at least one microprojection;
the backing member being detachable from the plunger distal end.
a damper positioned between the energy-storage devices and a proximal surface of the plunger distal end.
applying to a skin site of the subject, an applicator according to the combined or separate embodiments 46-68;
actuating the actuating member to convey an external force to the plunger element;
releasing the plunger element from the first restrained position to the second extended position;
rotating the torsional energy-mass system about the plunger shaft such that the system contacts the at least one projection on the plunger proximal surface and pushes it downward as the system rotates about the plunger shaft thereby to move the plunger distal end toward the skin site.
adhering the applicator to the subject's skin.
detaching a backing member such that the backing member and the at least one microprotrusion is retained on the subject's skin.
While a number of exemplary aspects and embodiments have been discussed above, those of skill in the art will recognize certain modifications, permutations, additions and sub-combinations thereof. It is therefore intended that the following appended claims and claims hereafter introduced are interpreted to include all such modifications, permutations, additions and sub-combinations as are within their true spirit and scope.
All patents, patent applications, and publications mentioned herein are hereby incorporated by reference in their entireties. However, where a patent, patent application, or publication containing express definitions is incorporated by reference, those express definitions should be understood to apply to the incorporated patent, patent application, or publication in which they are found, and not necessarily to the text of this application, in particular the claims of this application, in which instance, the definitions provided herein are meant to supersede.
This application claims the benefit of U.S. Provisional Application No. 61/801,904, filed Mar. 15, 2013, which is incorporated herein by reference in its entirety.
| Number | Name | Date | Kind |
|---|---|---|---|
| 1554510 | Kirby | Sep 1925 | A |
| 1770632 | Smith | Jul 1930 | A |
| 2046240 | Bayley | Jun 1936 | A |
| 2434407 | George | Jan 1948 | A |
| 3675766 | Rosenthal | Jul 1972 | A |
| 3704194 | Name | Nov 1972 | A |
| 3814097 | Ganderton et al. | Jun 1974 | A |
| 3873255 | Kalwaites | Mar 1975 | A |
| 3918449 | Pistor | Nov 1975 | A |
| 3964482 | Gerstel et al. | Jun 1976 | A |
| 4055029 | Kalbow | Oct 1977 | A |
| 4117841 | Perrotta et al. | Oct 1978 | A |
| 4151240 | Lucas et al. | Apr 1979 | A |
| 4180232 | Hardigg | Dec 1979 | A |
| 4342314 | Radel et al. | Aug 1982 | A |
| 4381963 | Goldstein et al. | May 1983 | A |
| 4395215 | Bishop | Jul 1983 | A |
| 4402696 | Gulko | Sep 1983 | A |
| 4460368 | Allison et al. | Jul 1984 | A |
| 4460370 | Allison et al. | Jul 1984 | A |
| 4463045 | Ahr et al. | Jul 1984 | A |
| 4509908 | Mullane, Jr. | Apr 1985 | A |
| 4515168 | Chester et al. | May 1985 | A |
| 4556441 | Faasse, Jr. | Dec 1985 | A |
| 4585991 | Reid et al. | Apr 1986 | A |
| 4597961 | Etscorn | Jul 1986 | A |
| 4609518 | Curro et al. | Sep 1986 | A |
| 4630603 | Greenway | Dec 1986 | A |
| 4660721 | Mykleby | Apr 1987 | A |
| 4695422 | Curro et al. | Sep 1987 | A |
| 4743234 | Leopoldi et al. | May 1988 | A |
| 4743249 | Loveland | May 1988 | A |
| 4784737 | Ray et al. | Nov 1988 | A |
| 4812305 | Vocal | Mar 1989 | A |
| 4837049 | Byers et al. | Jun 1989 | A |
| 4846821 | Lyons et al. | Jul 1989 | A |
| 4904475 | Gale et al. | Feb 1990 | A |
| 4996159 | Glaser | Feb 1991 | A |
| 5051259 | Olsen et al. | Sep 1991 | A |
| 5061258 | Martz | Oct 1991 | A |
| 5134079 | Cusack et al. | Jul 1992 | A |
| 5139029 | Fishman et al. | Aug 1992 | A |
| 5156591 | Gross et al. | Oct 1992 | A |
| 5158073 | Bukowski | Oct 1992 | A |
| 5160315 | Heinecke et al. | Nov 1992 | A |
| 5162043 | Lew et al. | Nov 1992 | A |
| 5163918 | Righi et al. | Nov 1992 | A |
| 5190558 | Matsushita et al. | Mar 1993 | A |
| 5198192 | Saito et al. | Mar 1993 | A |
| 5215088 | Normann et al. | Jun 1993 | A |
| 5244677 | Kreckel et al. | Sep 1993 | A |
| 5244711 | Drelich et al. | Sep 1993 | A |
| 5250023 | Lee et al. | Oct 1993 | A |
| 5250067 | Gelfer et al. | Oct 1993 | A |
| 5252279 | Gore et al. | Oct 1993 | A |
| 5256360 | Li | Oct 1993 | A |
| 5279544 | Gross et al. | Jan 1994 | A |
| 5308625 | Wong et al. | May 1994 | A |
| 5318557 | Gross | Jun 1994 | A |
| 5320600 | Lambert | Jun 1994 | A |
| 5330452 | Zook | Jul 1994 | A |
| 5362307 | Guy et al. | Nov 1994 | A |
| 5383512 | Jarvis | Jan 1995 | A |
| 5457041 | Ginaven et al. | Oct 1995 | A |
| 5462743 | Turner et al. | Oct 1995 | A |
| 5476443 | Cartmell et al. | Dec 1995 | A |
| 5487726 | Rabenau et al. | Jan 1996 | A |
| 5496304 | Chasan | Mar 1996 | A |
| 5498235 | Flower | Mar 1996 | A |
| 5503843 | Santus et al. | Apr 1996 | A |
| 5512219 | Rowland et al. | Apr 1996 | A |
| 5520629 | Heinecke et al. | May 1996 | A |
| 5527287 | Miskinyar | Jun 1996 | A |
| 5527288 | Gross et al. | Jun 1996 | A |
| 5531675 | Yoo | Jul 1996 | A |
| 5531855 | Heinecke et al. | Jul 1996 | A |
| 5536263 | Rolf et al. | Jul 1996 | A |
| 5551953 | Lattin et al. | Sep 1996 | A |
| 5567376 | Turi et al. | Oct 1996 | A |
| 5569469 | Lovrechich | Oct 1996 | A |
| 5591123 | Sibalis et al. | Jan 1997 | A |
| 5591139 | Lin et al. | Jan 1997 | A |
| 5611806 | Jang | Mar 1997 | A |
| 5645977 | Wu et al. | Jul 1997 | A |
| 5658515 | Lee et al. | Aug 1997 | A |
| 5662127 | De Vaughn | Sep 1997 | A |
| 5676850 | Reed et al. | Oct 1997 | A |
| 5681580 | Jang et al. | Oct 1997 | A |
| 5697901 | Ericksson | Dec 1997 | A |
| 5704520 | Gross | Jan 1998 | A |
| 5711761 | Untereker et al. | Jan 1998 | A |
| 5728089 | Lal et al. | Mar 1998 | A |
| 5730714 | Guy et al. | Mar 1998 | A |
| 5730721 | Hyatt et al. | Mar 1998 | A |
| 5735273 | Kurnik et al. | Apr 1998 | A |
| 5738642 | Heinecke et al. | Apr 1998 | A |
| 5756117 | D'Angelo et al. | May 1998 | A |
| 5771890 | Tamada | Jun 1998 | A |
| 5788983 | Chien et al. | Aug 1998 | A |
| 5800420 | Gross et al. | Sep 1998 | A |
| 5807375 | Gross et al. | Sep 1998 | A |
| 5814020 | Gross | Sep 1998 | A |
| 5820622 | Gross et al. | Oct 1998 | A |
| 5827183 | Kurnik et al. | Oct 1998 | A |
| 5843114 | Jang | Dec 1998 | A |
| 5848985 | Muroki | Dec 1998 | A |
| 5848990 | Cirelli et al. | Dec 1998 | A |
| 5848991 | Gross et al. | Dec 1998 | A |
| 5851549 | Svec | Dec 1998 | A |
| 5855801 | Lin et al. | Jan 1999 | A |
| 5868244 | Ivanov et al. | Feb 1999 | A |
| 5873849 | Bernard | Feb 1999 | A |
| 5879326 | Godshall et al. | Mar 1999 | A |
| 5900252 | Calanchi et al. | May 1999 | A |
| 5932240 | D'Angelo et al. | Aug 1999 | A |
| 5938684 | Lynch et al. | Aug 1999 | A |
| 5948488 | Marecki et al. | Sep 1999 | A |
| 5962011 | Devillez et al. | Oct 1999 | A |
| 5964729 | Choi et al. | Oct 1999 | A |
| 5983136 | Kamen | Nov 1999 | A |
| 5987989 | Yamamoto et al. | Nov 1999 | A |
| 5997549 | Sauceda et al. | Dec 1999 | A |
| 5997986 | Turi et al. | Dec 1999 | A |
| 6014584 | Hofmann et al. | Jan 2000 | A |
| 6023629 | Tamada | Feb 2000 | A |
| 6024553 | Shimalla | Feb 2000 | A |
| 6036659 | Ray et al. | Mar 2000 | A |
| 6038465 | Melton, Jr. | Mar 2000 | A |
| 6038485 | Axelgaard | Mar 2000 | A |
| 6047208 | Flower | Apr 2000 | A |
| 6050988 | Zuck | Apr 2000 | A |
| 6055453 | Hofmann et al. | Apr 2000 | A |
| 6080172 | Fujiwara et al. | Jun 2000 | A |
| 6083196 | Trautman et al. | Jul 2000 | A |
| 6091975 | Daddona et al. | Jul 2000 | A |
| 6106751 | Talbot et al. | Aug 2000 | A |
| 6120792 | Juni | Sep 2000 | A |
| 6129696 | Sibalis | Oct 2000 | A |
| 6132449 | Lum et al. | Oct 2000 | A |
| 6132755 | Eicher et al. | Oct 2000 | A |
| 6135990 | Heller et al. | Oct 2000 | A |
| 6136008 | Becker et al. | Oct 2000 | A |
| 6156336 | Bracht | Dec 2000 | A |
| 6169224 | Heinecke et al. | Jan 2001 | B1 |
| 6181964 | Hofmann et al. | Jan 2001 | B1 |
| 6183434 | Eppstein | Feb 2001 | B1 |
| 6183770 | Muchin et al. | Feb 2001 | B1 |
| 6187210 | Lebouitz et al. | Feb 2001 | B1 |
| 6216034 | Hofmann et al. | Apr 2001 | B1 |
| 6219574 | Cormier et al. | Apr 2001 | B1 |
| 6230051 | Cormier et al. | May 2001 | B1 |
| 6241701 | Hofmann | Jun 2001 | B1 |
| 6248120 | Wyszogrodzki | Jun 2001 | B1 |
| 6256533 | Yuzhakov et al. | Jul 2001 | B1 |
| 6293925 | Safabash et al. | Sep 2001 | B1 |
| 6312612 | Sherman et al. | Nov 2001 | B1 |
| 6322808 | Trautman et al. | Nov 2001 | B1 |
| 6334856 | Allen et al. | Jan 2002 | B1 |
| 6355054 | Neuberger | Mar 2002 | B1 |
| 6375627 | Mauze et al. | Apr 2002 | B1 |
| 6375870 | Visovsky et al. | Apr 2002 | B1 |
| 6375978 | Kleiner et al. | Apr 2002 | B1 |
| 6379324 | Garstein et al. | Apr 2002 | B1 |
| 6440096 | Lastovich et al. | Aug 2002 | B1 |
| 6451240 | Sherman et al. | Sep 2002 | B1 |
| 6471903 | Sherman et al. | Oct 2002 | B2 |
| 6476288 | Van Rijswijck et al. | Nov 2002 | B1 |
| 6485470 | Hostettler et al. | Nov 2002 | B2 |
| 6494830 | Wessel | Dec 2002 | B1 |
| 6503231 | Prausnitz et al. | Jan 2003 | B1 |
| 6508947 | Gulvin et al. | Jan 2003 | B2 |
| 6511463 | Wood et al. | Jan 2003 | B1 |
| 6512626 | Schmidt | Jan 2003 | B1 |
| 6516223 | Hofmann | Feb 2003 | B2 |
| 6532386 | Sun et al. | Mar 2003 | B2 |
| 6533884 | Mallik | Mar 2003 | B1 |
| 6537242 | Palmer | Mar 2003 | B1 |
| 6537264 | Cormier et al. | Mar 2003 | B1 |
| 6558361 | Yeshurun | May 2003 | B1 |
| 6562014 | Lin et al. | May 2003 | B2 |
| 6565532 | Yuzhakov et al. | May 2003 | B1 |
| 6585742 | Stough | Jul 2003 | B2 |
| 6589202 | Powell | Jul 2003 | B1 |
| 6591124 | Sherman et al. | Jul 2003 | B2 |
| 6591133 | Joshi | Jul 2003 | B1 |
| 6603987 | Whiston | Aug 2003 | B2 |
| 6610463 | Ohkura et al. | Aug 2003 | B1 |
| 6611706 | Avrahami et al. | Aug 2003 | B2 |
| 6611707 | Prausnitz et al. | Aug 2003 | B1 |
| 6623457 | Rosenberg | Sep 2003 | B1 |
| 6629949 | Douglas | Oct 2003 | B1 |
| 6652478 | Gartstein et al. | Nov 2003 | B1 |
| 6656147 | Gertsek et al. | Dec 2003 | B1 |
| 6663820 | Arias et al. | Dec 2003 | B2 |
| 6685682 | Heinecke et al. | Feb 2004 | B1 |
| 6689103 | Palasis | Feb 2004 | B1 |
| 6691752 | DiSabatino | Feb 2004 | B2 |
| 6743211 | Prausnitz et al. | Jun 2004 | B1 |
| 6767341 | Cho | Jul 2004 | B2 |
| 6770480 | Canham | Aug 2004 | B1 |
| 6778853 | Heller et al. | Aug 2004 | B1 |
| 6780171 | Gabel et al. | Aug 2004 | B2 |
| 6808506 | Lastovich et al. | Oct 2004 | B2 |
| 6821281 | Sherman et al. | Nov 2004 | B2 |
| 6835184 | Sage et al. | Dec 2004 | B1 |
| 6855131 | Trautman et al. | Feb 2005 | B2 |
| 6881203 | Delmore et al. | Apr 2005 | B2 |
| 6931277 | Yuzhakov et al. | Aug 2005 | B1 |
| 6945952 | Kwon | Sep 2005 | B2 |
| 6960193 | Rosenberg | Nov 2005 | B2 |
| 6980855 | Cho et al. | Dec 2005 | B2 |
| 6991809 | Anderson | Jan 2006 | B2 |
| 7011844 | Gale et al. | Mar 2006 | B2 |
| 7062317 | Avrahami et al. | Jun 2006 | B2 |
| 7087035 | Trautman et al. | Aug 2006 | B2 |
| 7097631 | Trautman et al. | Aug 2006 | B2 |
| 7108681 | Gartstein et al. | Sep 2006 | B2 |
| 7115108 | Wilkinson et al. | Oct 2006 | B2 |
| 7128730 | Marano-Ford et al. | Oct 2006 | B2 |
| 7131960 | Trautman et al. | Nov 2006 | B2 |
| 7131987 | Sherman et al. | Nov 2006 | B2 |
| 7166086 | Haider et al. | Jan 2007 | B2 |
| 7184826 | Cormier et al. | Feb 2007 | B2 |
| 7186235 | Martin et al. | Mar 2007 | B2 |
| 7226439 | Prausnitz et al. | Jun 2007 | B2 |
| 7332339 | Canham | Feb 2008 | B2 |
| 7412284 | Hofmann | Aug 2008 | B2 |
| 7416541 | Yuzhakov et al. | Aug 2008 | B2 |
| 7419481 | Trautman et al. | Sep 2008 | B2 |
| 7572405 | Sherman et al. | Aug 2009 | B2 |
| 7578954 | Gartstein et al. | Aug 2009 | B2 |
| 7578985 | Gartstein et al. | Aug 2009 | B2 |
| 7611481 | Cleary et al. | Nov 2009 | B2 |
| 7658728 | Yuzhakov | Feb 2010 | B2 |
| 7678777 | Yasuda et al. | Mar 2010 | B2 |
| 7763203 | Arias et al. | Jul 2010 | B2 |
| 7785301 | Yuzhakov | Aug 2010 | B2 |
| 7789733 | Sugimura | Sep 2010 | B2 |
| 7798987 | Trautman et al. | Sep 2010 | B2 |
| 7828827 | Gartstein et al. | Nov 2010 | B2 |
| 7846488 | Johnson | Dec 2010 | B2 |
| 7914480 | Cleary et al. | Mar 2011 | B2 |
| 8057842 | Choi et al. | Nov 2011 | B2 |
| 8062573 | Kwon | Nov 2011 | B2 |
| 8216190 | Gartstein et al. | Jul 2012 | B2 |
| 8267889 | Cantor et al. | Sep 2012 | B2 |
| 8366677 | Kaspar et al. | Feb 2013 | B2 |
| 8696638 | Terahara et al. | Apr 2014 | B2 |
| 8702726 | Gartstein et al. | Apr 2014 | B2 |
| 8734697 | Chen et al. | May 2014 | B2 |
| 8747362 | Terahara | Jun 2014 | B2 |
| 8771781 | Tokumoto et al. | Jul 2014 | B2 |
| 8821446 | Trautman et al. | Sep 2014 | B2 |
| 8834423 | Falo, Jr. et al. | Sep 2014 | B2 |
| 8900180 | Wolter et al. | Dec 2014 | B2 |
| 8911749 | Gharty-Tagoe et al. | Dec 2014 | B2 |
| 9114238 | Singh et al. | Aug 2015 | B2 |
| 9220678 | Kendall et al. | Dec 2015 | B2 |
| 9452280 | Singh et al. | Sep 2016 | B2 |
| 9498524 | Ghartey-Tagoe et al. | Nov 2016 | B2 |
| 9687640 | Trautman et al. | Jun 2017 | B2 |
| 9687641 | Singh et al. | Jun 2017 | B2 |
| 20010023324 | Pronovost et al. | Sep 2001 | A1 |
| 20010023351 | Eilers et al. | Sep 2001 | A1 |
| 20020006355 | Whitson | Jan 2002 | A1 |
| 20020016562 | Cormier et al. | Feb 2002 | A1 |
| 20020020688 | Sherman et al. | Feb 2002 | A1 |
| 20020032415 | Trautman et al. | Mar 2002 | A1 |
| 20020042589 | Marsoner | Apr 2002 | A1 |
| 20020045859 | Gartstein et al. | Apr 2002 | A1 |
| 20020045907 | Sherman et al. | Apr 2002 | A1 |
| 20020082543 | Park et al. | Jun 2002 | A1 |
| 20020087182 | Trautman et al. | Jul 2002 | A1 |
| 20020091357 | Trautman et al. | Jul 2002 | A1 |
| 20020096488 | Gulvin et al. | Jul 2002 | A1 |
| 20020123675 | Trautman et al. | Sep 2002 | A1 |
| 20020133129 | Arias et al. | Sep 2002 | A1 |
| 20020133137 | Hofmann | Sep 2002 | A1 |
| 20020138049 | Allen et al. | Sep 2002 | A1 |
| 20020169411 | Sherman et al. | Nov 2002 | A1 |
| 20020177839 | Cormier et al. | Nov 2002 | A1 |
| 20020177858 | Sherman et al. | Nov 2002 | A1 |
| 20020188245 | Martin et al. | Dec 2002 | A1 |
| 20020188310 | Seward et al. | Dec 2002 | A1 |
| 20020193729 | Cormier et al. | Dec 2002 | A1 |
| 20020193819 | Porter et al. | Dec 2002 | A1 |
| 20030083645 | Angel | May 2003 | A1 |
| 20030093028 | Spiegel | May 2003 | A1 |
| 20030093089 | Greenberg | May 2003 | A1 |
| 20030135167 | Gonnelli | Jul 2003 | A1 |
| 20030166624 | Gale et al. | Sep 2003 | A1 |
| 20030187394 | Wilkinson et al. | Oct 2003 | A1 |
| 20030195474 | Down et al. | Oct 2003 | A1 |
| 20030199810 | Trautman et al. | Oct 2003 | A1 |
| 20030199812 | Rosenberg | Oct 2003 | A1 |
| 20030208138 | Olson | Nov 2003 | A1 |
| 20030208167 | Prausnitz et al. | Nov 2003 | A1 |
| 20030212397 | Avrahami et al. | Nov 2003 | A1 |
| 20030220610 | Lastovich et al. | Nov 2003 | A1 |
| 20030220656 | Gartstein et al. | Nov 2003 | A1 |
| 20040049150 | Dalton et al. | Mar 2004 | A1 |
| 20040062813 | Cormier et al. | Apr 2004 | A1 |
| 20040087893 | Kwon | May 2004 | A1 |
| 20040087992 | Gartstein et al. | May 2004 | A1 |
| 20040096455 | Maa et al. | May 2004 | A1 |
| 20040106904 | Gonnelli et al. | Jun 2004 | A1 |
| 20040143211 | Haider et al. | Jul 2004 | A1 |
| 20040146611 | Arias et al. | Jul 2004 | A1 |
| 20040164454 | Gartstein et al. | Aug 2004 | A1 |
| 20040181203 | Cormier et al. | Sep 2004 | A1 |
| 20040186419 | Cho | Sep 2004 | A1 |
| 20040204669 | Hofmann | Oct 2004 | A1 |
| 20040220535 | Canham | Nov 2004 | A1 |
| 20040236271 | Theeuwes et al. | Nov 2004 | A1 |
| 20040265365 | Daddona et al. | Dec 2004 | A1 |
| 20050049549 | Wong et al. | Mar 2005 | A1 |
| 20050065463 | Tobinga et al. | Mar 2005 | A1 |
| 20050089554 | Cormier et al. | Apr 2005 | A1 |
| 20050090803 | Sherman et al. | Apr 2005 | A1 |
| 20050096586 | Trautman et al. | May 2005 | A1 |
| 20050163827 | Zech et al. | Jul 2005 | A1 |
| 20050178760 | Chang et al. | Aug 2005 | A1 |
| 20050197308 | Dalton | Sep 2005 | A1 |
| 20050209565 | Yuzhakov et al. | Sep 2005 | A1 |
| 20050228340 | Cleary et al. | Oct 2005 | A1 |
| 20050256045 | Ameri et al. | Nov 2005 | A1 |
| 20050261631 | Clarke et al. | Nov 2005 | A1 |
| 20060024358 | Santini et al. | Feb 2006 | A1 |
| 20060067943 | Maa et al. | Mar 2006 | A1 |
| 20060076718 | Sherman et al. | Apr 2006 | A1 |
| 20060095061 | Trautman et al. | May 2006 | A1 |
| 20060108914 | Young | May 2006 | A1 |
| 20060129174 | Gartstein et al. | Jun 2006 | A1 |
| 20060134188 | Podhaisky et al. | Jun 2006 | A1 |
| 20060149297 | Sherman et al. | Jul 2006 | A1 |
| 20060253079 | McDonough | Nov 2006 | A1 |
| 20070027427 | Trautman et al. | Feb 2007 | A1 |
| 20070191761 | Boone et al. | Aug 2007 | A1 |
| 20070255251 | Panchula et al. | Nov 2007 | A1 |
| 20080009811 | Cantor | Jan 2008 | A1 |
| 20080009825 | Ringsred et al. | Jan 2008 | A1 |
| 20080039805 | Frederickson et al. | Feb 2008 | A1 |
| 20080114298 | Cantor et al. | May 2008 | A1 |
| 20080125743 | Yuzhakov | May 2008 | A1 |
| 20080183144 | Trautman et al. | Jul 2008 | A1 |
| 20080188771 | Boecker | Aug 2008 | A1 |
| 20080195035 | Frederickson et al. | Aug 2008 | A1 |
| 20080208134 | Tomono | Aug 2008 | A1 |
| 20080208146 | Brandwein et al. | Aug 2008 | A1 |
| 20080214987 | Xu | Sep 2008 | A1 |
| 20080221532 | Ogawa | Sep 2008 | A1 |
| 20080269685 | Singh et al. | Oct 2008 | A1 |
| 20090017210 | Andrianov et al. | Jan 2009 | A1 |
| 20090035446 | Kwon | Feb 2009 | A1 |
| 20090041810 | Andrianov et al. | Feb 2009 | A1 |
| 20090043279 | Kaspar et al. | Feb 2009 | A1 |
| 20090155330 | Ghartey-Tagoe et al. | Jun 2009 | A1 |
| 20090182306 | Lee et al. | Jul 2009 | A1 |
| 20090216215 | Thalmann et al. | Aug 2009 | A1 |
| 20100028390 | Cleary et al. | Feb 2010 | A1 |
| 20100200494 | Storer | Aug 2010 | A1 |
| 20100228203 | Quan et al. | Sep 2010 | A1 |
| 20100247698 | Zhang et al. | Sep 2010 | A1 |
| 20110006458 | Sagi et al. | Jan 2011 | A1 |
| 20110028905 | Takada | Feb 2011 | A1 |
| 20110046638 | Gartstein et al. | Feb 2011 | A1 |
| 20110059150 | Kendall et al. | Mar 2011 | A1 |
| 20110098651 | Falo et al. | Apr 2011 | A1 |
| 20110121486 | Oh et al. | May 2011 | A1 |
| 20110160069 | Carrie et al. | Jun 2011 | A1 |
| 20110177139 | Hyungil et al. | Jul 2011 | A1 |
| 20110276027 | Trautman et al. | Nov 2011 | A1 |
| 20110276028 | Singh et al. | Nov 2011 | A1 |
| 20110280800 | Wu et al. | Nov 2011 | A1 |
| 20110288484 | Kendall et al. | Nov 2011 | A1 |
| 20110288485 | Tokumoto et al. | Nov 2011 | A1 |
| 20110306853 | Black | Dec 2011 | A1 |
| 20120052120 | Castor | Mar 2012 | A1 |
| 20120123387 | Gonzalez | May 2012 | A1 |
| 20120126297 | Brancazio | May 2012 | A1 |
| 20120130306 | Terahara et al. | May 2012 | A1 |
| 20120150023 | Kaspar et al. | Jun 2012 | A1 |
| 20120184906 | McAllister | Jul 2012 | A1 |
| 20120330250 | Kuwahara | Dec 2012 | A1 |
| 20130131598 | Trautman et al. | May 2013 | A1 |
| 20130287832 | O'Hagan et al. | Oct 2013 | A1 |
| 20130292868 | Singh et al. | Nov 2013 | A1 |
| 20130292886 | Sagi et al. | Nov 2013 | A1 |
| 20130303502 | Cavanagh et al. | Nov 2013 | A1 |
| 20140148846 | Pereira et al. | May 2014 | A1 |
| 20140180201 | Ding et al. | Jun 2014 | A1 |
| 20140248312 | Rappuoli et al. | Sep 2014 | A1 |
| 20140257188 | Kendall et al. | Sep 2014 | A1 |
| 20140272101 | Chen et al. | Sep 2014 | A1 |
| 20140276366 | Bourne et al. | Sep 2014 | A1 |
| 20140276378 | Chen et al. | Sep 2014 | A1 |
| 20140276474 | Ding et al. | Sep 2014 | A1 |
| 20140276580 | Le et al. | Sep 2014 | A1 |
| 20140276589 | Bayramov et al. | Sep 2014 | A1 |
| 20150079133 | Ghartey-Tagoe et al. | Mar 2015 | A1 |
| 20150238413 | Mochizuki et al. | Aug 2015 | A1 |
| 20150297878 | Singh et al. | Oct 2015 | A1 |
| 20160058992 | Chen et al. | Mar 2016 | A1 |
| 20160067176 | Ding et al. | Mar 2016 | A1 |
| 20160135895 | Faasse et al. | May 2016 | A1 |
| 20160175572 | Crowley et al. | Jun 2016 | A1 |
| 20160374939 | Shastry et al. | Dec 2016 | A1 |
| 20170281535 | Singh et al. | Oct 2017 | A1 |
| 20170361079 | Trautman et al. | Dec 2017 | A1 |
| Number | Date | Country |
|---|---|---|
| 2205444 | Jun 1996 | CA |
| 2376285 | Dec 2000 | CA |
| 2316534 | Mar 2001 | CA |
| 2422907 | Apr 2002 | CA |
| 2889500 | May 2014 | CA |
| 102000020 | Jun 2011 | CN |
| 102580232 | Jul 2012 | CN |
| 02319591 | Nov 1974 | DE |
| 19518974 | Nov 1995 | DE |
| 19624578 | Jan 1998 | DE |
| 0156471 | Oct 1985 | EP |
| 0240593 | Oct 1987 | EP |
| 0301599 | Feb 1989 | EP |
| 0305123 | Mar 1989 | EP |
| 0312662 | Apr 1989 | EP |
| 0400249 | Dec 1990 | EP |
| 0407063 | Jan 1991 | EP |
| 0796128 | Sep 1997 | EP |
| 1086718 | Mar 2001 | EP |
| 1086719 | Mar 2001 | EP |
| 1174078 | Jan 2002 | EP |
| 2283809 | Feb 2011 | EP |
| 2399624 | Dec 2011 | EP |
| 2535602 | May 1984 | FR |
| 0783479 | Sep 1957 | GB |
| 2221394 | Feb 1990 | GB |
| 2277202 | Oct 1994 | GB |
| 46-037758 | Dec 1971 | JP |
| 60-242042 | Dec 1985 | JP |
| 62-213763 | Sep 1987 | JP |
| 01-264839 | Oct 1989 | JP |
| 02-009755 | Mar 1990 | JP |
| 03-151951 | Jun 1991 | JP |
| 05-123326 | May 1993 | JP |
| 05-162076 | Jun 1993 | JP |
| 06-238644 | Aug 1994 | JP |
| 07-132119 | May 1995 | JP |
| 08-502215 | Mar 1996 | JP |
| 09-051878 | Feb 1997 | JP |
| 54-028369 | Mar 1997 | JP |
| 09-140687 | Jun 1997 | JP |
| 09-211022 | Aug 1997 | JP |
| 10-328168 | Dec 1998 | JP |
| 11-230707 | Aug 1999 | JP |
| 11-509123 | Aug 1999 | JP |
| 2000-146777 | May 2000 | JP |
| 2000-147229 | May 2000 | JP |
| 2000-164890 | Jun 2000 | JP |
| 2000-194142 | Jul 2000 | JP |
| 2000-232095 | Aug 2000 | JP |
| 2000-232971 | Aug 2000 | JP |
| 2000-322780 | Nov 2000 | JP |
| 2000-323461 | Nov 2000 | JP |
| 2001-004442 | Jan 2001 | JP |
| 2001-138300 | May 2001 | JP |
| 2001-149485 | Jun 2001 | JP |
| 2001-157715 | Jun 2001 | JP |
| 2001-341314 | Dec 2001 | JP |
| 2002-000728 | Jan 2002 | JP |
| 2002-079499 | Mar 2002 | JP |
| 2002-151395 | May 2002 | JP |
| 2002-239014 | Aug 2002 | JP |
| 2002-301698 | Oct 2002 | JP |
| 2003-039399 | Feb 2003 | JP |
| 2003-048160 | Feb 2003 | JP |
| 2003-534881 | Nov 2003 | JP |
| 2004-065775 | Mar 2004 | JP |
| 2007-190112 | Jan 2006 | JP |
| 2006271781 | Oct 2006 | JP |
| 2006-341089 | Dec 2006 | JP |
| 2007-130030 | May 2007 | JP |
| 2007-536988 | Dec 2007 | JP |
| 2008-006178 | Jan 2008 | JP |
| 2008-074763 | Apr 2008 | JP |
| 2008-194288 | Aug 2008 | JP |
| 2009-082206 | Apr 2009 | JP |
| 2009-082207 | Apr 2009 | JP |
| 2009-201956 | Sep 2009 | JP |
| 2010-233673 | Oct 2010 | JP |
| 2010-233674 | Oct 2010 | JP |
| 20100064669 | Jun 2010 | KR |
| 2414255 | Mar 2011 | RU |
| 1641346 | Apr 1991 | SU |
| 1667864 | Aug 1991 | SU |
| WO 1993015701 | Aug 1993 | WO |
| WO 1993017754 | Sep 1993 | WO |
| WO 1994023777 | Oct 1994 | WO |
| WO 1995022612 | Aug 1995 | WO |
| WO 1995033612 | Dec 1995 | WO |
| WO 1996000109 | Apr 1996 | WO |
| WO 1996017648 | Jun 1996 | WO |
| WO 1996037155 | Nov 1996 | WO |
| WO 1996037256 | Nov 1996 | WO |
| WO 1997003629 | Feb 1997 | WO |
| WO 1997003718 | Feb 1997 | WO |
| WO 1997013544 | Apr 1997 | WO |
| WO 1997048440 | Dec 1997 | WO |
| WO 1997048441 | Dec 1997 | WO |
| WO 1997048442 | Dec 1997 | WO |
| WO 1998000193 | Jan 1998 | WO |
| WO 1998028307 | Jul 1998 | WO |
| WO 1999000155 | Jan 1999 | WO |
| WO 1999029298 | Jun 1999 | WO |
| WO 1999029364 | Jun 1999 | WO |
| WO 1999029365 | Jun 1999 | WO |
| WO 1999049874 | Oct 1999 | WO |
| WO 1999061888 | Dec 1999 | WO |
| WO 1999064580 | Dec 1999 | WO |
| WO 2000005166 | Feb 2000 | WO |
| WO 2003026733 | Apr 2000 | WO |
| WO 2000035530 | Jun 2000 | WO |
| WO 2000070406 | Nov 2000 | WO |
| WO 2000074763 | Dec 2000 | WO |
| WO 2000074764 | Dec 2000 | WO |
| WO 2000074765 | Dec 2000 | WO |
| WO 2000074766 | Dec 2000 | WO |
| WO 2000077571 | Dec 2000 | WO |
| WO 2001008242 | Feb 2001 | WO |
| WO 2001036037 | May 2001 | WO |
| WO 2001036321 | May 2001 | WO |
| WO 2001049362 | Jul 2001 | WO |
| WO 2002002180 | Jan 2002 | WO |
| WO 2002007543 | Jan 2002 | WO |
| WO 2002007813 | Jan 2002 | WO |
| WO 2002017985 | Mar 2002 | WO |
| WO 2002030301 | Apr 2002 | WO |
| WO 2002032331 | Apr 2002 | WO |
| WO 2002032480 | Apr 2002 | WO |
| WO 2002062202 | Aug 2002 | WO |
| WO 2002064193 | Aug 2002 | WO |
| WO 2002072189 | Sep 2002 | WO |
| WO 2002085446 | Oct 2002 | WO |
| WO 2002091922 | Nov 2002 | WO |
| WO 2002100474 | Dec 2002 | WO |
| WO 2003024290 | Mar 2003 | WO |
| WO 2003024518 | Mar 2003 | WO |
| WO 2004000389 | Dec 2003 | WO |
| WO 2004009172 | Jan 2004 | WO |
| WO 2004024224 | Mar 2004 | WO |
| WO 2004030649 | Apr 2004 | WO |
| WO 2004076339 | Sep 2004 | WO |
| WO 2004105729 | Dec 2004 | WO |
| WO 2004110717 | Dec 2004 | WO |
| WO 2005002453 | Jan 2005 | WO |
| WO 2005046769 | May 2005 | WO |
| WO 2005065765 | Jul 2005 | WO |
| WO 2005082596 | Sep 2005 | WO |
| WO 2005089857 | Sep 2005 | WO |
| WO 2005094526 | Oct 2005 | WO |
| WO 2005099751 | Oct 2005 | WO |
| WO 2005112984 | Dec 2005 | WO |
| WO 2006020842 | Feb 2006 | WO |
| WO 2006055795 | May 2006 | WO |
| WO 2006062848 | Jun 2006 | WO |
| WO 2006086742 | Aug 2006 | WO |
| WO 2006101459 | Sep 2006 | WO |
| WO 2007002521 | Jan 2007 | WO |
| WO 2007002522 | Jan 2007 | WO |
| WO 2007002523 | Jan 2007 | WO |
| WO 2007012114 | Feb 2007 | WO |
| WO 2007030477 | Mar 2007 | WO |
| WO 2007061964 | May 2007 | WO |
| WO 2007061972 | May 2007 | WO |
| WO 2007075806 | Jul 2007 | WO |
| WO 2007081430 | Jul 2007 | WO |
| WO 2007124411 | Nov 2007 | WO |
| WO 2008011625 | Jan 2008 | WO |
| WO 2008015236 | Feb 2008 | WO |
| WO 2008024141 | Feb 2008 | WO |
| WO 2008091602 | Jul 2008 | WO |
| WO 2008130587 | Oct 2008 | WO |
| WO 2008139648 | Nov 2008 | WO |
| WO 2009039013 | Mar 2009 | WO |
| WO 2009048507 | Apr 2009 | WO |
| WO 2009054988 | Apr 2009 | WO |
| WO 2009142741 | Nov 2009 | WO |
| WO 2010040271 | Apr 2010 | WO |
| WO 2010124255 | Oct 2010 | WO |
| WO 2011121023 | Oct 2011 | WO |
| WO 2011140240 | Oct 2011 | WO |
| WO 2011140274 | Oct 2011 | WO |
| WO 2012054582 | Apr 2012 | WO |
| WO 2012122163 | Sep 2012 | WO |
| WO 2012127249 | Sep 2012 | WO |
| WO 2012153266 | Nov 2012 | WO |
| WO 2013172999 | Nov 2013 | WO |
| WO 2014004301 | Jan 2014 | WO |
| WO 2014077244 | May 2014 | WO |
| WO 2014100750 | Jun 2014 | WO |
| WO 2014144973 | Sep 2014 | WO |
| WO 2014150069 | Sep 2014 | WO |
| WO 2014150285 | Sep 2014 | WO |
| WO 2014151654 | Sep 2014 | WO |
| WO 2014164314 | Oct 2014 | WO |
| WO 2016033540 | Mar 2016 | WO |
| WO 2016036866 | Mar 2016 | WO |
| WO 2016073908 | May 2016 | WO |
| WO 2017004067 | Jan 2017 | WO |
| Entry |
|---|
| Avcin et al., “Subcutaneous nodule after vaccination with an aluminum-containing vaccine”, Acta Dermatoven, APA, vol. 17, No. 4, pp. 182-184 (2008). |
| Corbett et al., “Skin vaccination against cervical cancer associated human papillomavirus with a novel micro-projection array in a mouse model”, PLOS one,vol. 5, No. 10, pp. 1-9 (2010). |
| Database WPI / Thomson, Accession No. 2014-V89218, Gao et al., “Soluble microneedle patch useful for transdermal administration of vaccine, comprises water-soluble polymer material as matrix material and soluble microneedle main portion”, Application No. CN104027324A, Tech Inst Phys. & Chem. Chinese Acad., 3 pages (2014). |
| Ghosh et al., “Influence of critical parameters of nanosuspension formulation on permeability of a poorly soluble drug through the skin—A case study”, vol. 14, No. 3, pp. 1108-1117 (2013). |
| Guo et al., “Enhanced transcutaneous immunization via dissolving microneedie array loaded with liposome encapsulated antigen and adjuvant”, Int. J. Pharm., vol. 447, No. 1-2, pp. 22-30 (2013). |
| Gupta, “Aluminum compounds as vaccine adjuvants”, Adv. Drug Deliv. Rev., vol. 32, No. 3, pp. 155-172 (1998) Abstract Only. |
| Gupta and Rost, “Aluminum compounds as vaccine adjuvants”, Vaccine adjuvants: Preparation Methods and Research Protocols, O'Hagan, ed., Humana Press, Inc., Totowa, New Jersey, Meth. Mol. Med., vol. 42, No. 4, No. 4, pp. 65-89 (2000). |
| International Search Report from International Patent Application No. PCT/US2014/022836 dated May 9, 2015. |
| International Search Report from International Patent Application No. PCT/US2015/047563 dated Nov. 20, 2015. |
| International Search Report from International Patent Application No. PCT/US2015/048161 dated Nov. 26, 2015. |
| Kuroda et al., “Particulate adjuvant and innate immunity: past achievements, present findings, and future prospects”, Int. Rev. Immunol., vol. 32, No. 2, pp. 209-220 (2013). |
| Munks et al., “Aluminum adjuvants elicit fibrin-dependent extracellular traps in vivo”, Blood, vol. 116, No. 24, pp. 5191-5199 (2010). |
| Petrovsky and Aguilar, “Vaccine adjuvants: current state and future trends”, Immunol. Cell Biol., vol. 82, No. 5, pp. 488-496 (2004). |
| Pittman, “Aluminum-containing vaccine associated adverse events: role of route of administration and gender”, Vaccine, vol. 20, pp. s48-s50 (2002). |
| Prausnitz, “Microneedle-based vaccines”, Curr. Top. Microbiol. Immunol., vol. 333, pp. 369-393 (2009). |
| Sayers et al., “Vaxjo: A Web-Based Vaccine Adjuvant Database and Its Application for Analysis of Vaccine Adjuvants and Their Uses in Vaccine Development”, J. Biomed. Biotechnol., vol. 2012, Article ID: 831486, 13 pages, doi:10.1155/2012/831486 (2011). |
| White et al., “Studies on antibody production. III. The alum granuloma”, J. Exp. Med., vol. 102, No. 1, pp. 73-82 (1955). |
| International Search Report from International Patent Application No. PCT/US2015/059559 dated Jan. 21, 2016. |
| Keitel et al., “A randomized clinical trail of acellular pertussis vaccines in healthy adults: Dose-response comparisons of 5 vaccines and implications for booster immunization”, J. Infect. Dis., vol. 180, pp. 397-403 (1999). |
| Lutrol F 68 NF, BASF Pharma Ingredients, accessed from the internet on Sep. 5, 2016 from http://www2.basf.us/Pharma/pdf/Lutrol_F_68.pdf. |
| Vitiello et al., “Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection”, J. Clin. Invest., vol. 95, pp. 341-349 (1995). |
| “Eudragit EPO Readymix—Taste masking and moisture protection have never been easier” Evonik Industries, Evonik industries AG, Pharma Polymers & Services. Nov. 2014. |
| International Search Report from International Patent Application No. PCT/US2014/022859 dated May 26, 2014. |
| International Search Report from International Patent Application No. PCT/US2014/021841 dated Aug. 11, 2014. |
| International Search Report from International Patent Application No. PCT/US2014/026179 dated Jul. 18, 2014. |
| International Search Report from International Patent Application No. PCT/US2014/029601 dated Jul. 1, 2014. |
| Chun, et al., “An array of hollow microcapilaries for the controlled injection of genetic materials into animal/plant cells.” IEEE Workshop on Micro Electro Mechnical Systems, pp. 406-411, (1999). |
| “Extend”, Merriam-Webster Online Dictionary, 6 pages. Downloaded on Sep. 7, 2010 from <http://www.merriam-webster.com/dictionary/extend>. |
| “Extend”, Macmillan Online Dictionary, 5 pages. Downloaded on Sep. 7, 2010 from <http://www.macmillandictionary.com/dictionary/american/extend>. |
| Henry et al., “Micromachined microneedles for transdermal delivery of drugs”, IEEE Workshop on Micro Electro Mechanical Systems, New York, NY, pp. 494-498, (1998). |
| Henry, et al., “Microfabricated microneedles: A novel approach to transdermal drug delivery”, J. Pharmaceutical Science, vol. 87, No. 8, pp. 922-925, (1998). |
| “Heparin Pregnancy and Breast Feeding Warnings”, Drugs.com, Accessed Oct. 8, 2009, <http://www.drugs.com/pregnancy/heparin.html>. |
| International Search Report from International Patent Application No. PCT/US2000/015612 dated Sep. 7, 2000. |
| International Search Report from International Patent Application No. PCT/US2000/015613 dated Sep. 6, 2000. |
| International Search Report from International Patent Application No. PCT/US2000/015614 dated Sep. 6, 2000. |
| International Search Report from International Patent Application No. PCT/US2001/031977 dated Apr. 29, 2002. |
| International Search Report from International Patent Application No. PCT/US2001/031978 dated Apr. 29, 2002. |
| International Search Report from International Patent Application No. PCT/US2002/014624 dated Sep. 3, 2002. |
| International Search Report from International Patent Application No. PCT/US2002/029228 dated Apr. 23, 2003. |
| International Search Report from International Patent Application No. PCT/US2002/029245 dated Dec. 27, 2002. |
| International Search Report from International Patent Application No. PCT/US2004/005382 dated Nov. 25, 2004. |
| International Search Report from International Patent Application No. PCT/US2004/017255 dated May 24, 2005. |
| International Search Report from International Patent Application No. PCT/US2005/009654 dated Jul. 3, 2008. |
| International Search Report from International Patent Application No. PCT/US2008/000824 dated Jul. 18, 2008. |
| International Search Report from International Patent Application No. PCT/US2008/004943 dated Jun. 9, 2009, application now published as International Publication No. WO2008/130587 Oct. 30, 2008. |
| International Search Report from International Patent Application No. PCT/US2008/011635 dated Dec. 19, 2008, application now published as International Publication No. WO2009/048607 on Apr. 16, 2009. |
| International Search Report from International Patent Application No. PCT/US2010/032299 dated Dec. 10, 2010, application now published as International Publication No. WO2010/124255 on Oct. 28, 2010. |
| International Search Report from International Patent Application No. PCT/US2013/077281 dated Mar. 4, 2013. |
| International Search Report from International Patent Application No. PCT/US2014/022087 dated May 23, 2014. |
| Matriano, et al., “Macroflux(R) microprojection array patch technology: A new and efficient approach for intracutaneous immunization”, Pharm. Res., vol. 19, No. 1, pp. 63-70, (2002). |
| McAllister, et al., “Micromachined microneedles for transdermal drug delivery”, Am. Inst. Chem. Eng., 1998 Annual Meeting, Miami Beach, FL, Nov. 15-20, Drug Delivery II, pp. 1-4. |
| Mikszta, et al., “Improved genetic immunization via micromechanical disruption of skin-barrier function and targeted epidermal delivery”, Nat. Med., vol. 8, No. 4, pp. 415-419, (2002). |
| Mikszta, et al., “Protective immunization against inhalation anthrax: A comparison of minimally invasive delivery platforms”, J. Inf. Dis., vol. 191, No. 2, pp. 278-288, (2005). |
| Papautsky, et al., “Micromachined Pipette Arrays,” MPA, Proceedings—19th International Conference—IEEE/EMBS, Chicago, IL, USA, pp. 2281-2284 (1997). |
| Park et al., “Biodegradable polymer microneedles: Fabrication, mechanics, and transdermal drug delivery”, J. Contr. Rel., vol. 104, pp. 51-66 (2005). |
| Park, et al. “Polymer Microneedles for Controlled-Release Drug Delivery,” Pharmaceutical Research, Kluwer Academic Publishers—Plenum Publishers, NE, vol. 23, No. 5, pp. 1008-1019 (2006). |
| Prausnitz, et al., “Transdermal transport efficiency during skin electroporation and iontophoresis”, J. Contr. Release, vol. 38, pp. 205-217, (1996). |
| Prausnitz, “Transdermal delivery of macromolecules: Recent advances by modification of skin's barrier properties”, ACS Symposium Series No. 675, Therapeutic Protein and Peptide Formulation and Delivery, American Chemical Soceity, Washington DC, Chapter 8, pp. 124-153, (1997). |
| Rydberg, et al., “Low-molecular-weight heparin preventing and treating DVT”, Am. Fam. Physician, vol. 59, No. 6, pp. 1607-1612, (1999). |
| Sivamani, et al., “Microneedles and transdermal applications”, Exp. Opin, Drug Del., vol. 4, No. 1, pp. 19-25, (2007). |
| Wouters, et al., “Microelectrochemical systems for drug delivery”, Electrochimica Acta., vol. 42, pp. 3385-3390, (1997). |
| Xia, et al., “Soft Lithography”, Agnew. Chem. Int. Ed, vol. 37, pp. 551-575, (1998). |
| Xia, et al., “Soft Lithography”, Annu. Rev. Mater. Sci., vol. 28, pp. 153-184 (1998). |
| International Search Report from International Patent Application No. PCT/US2011/035221 dated Jan. 10, 2012, application now published as International Publication No. WO2011/140240 on Nov. 10, 2011. |
| International Search Report from International Patent Application No. PCT/US2016/039864 dated Sep. 23, 2016. |
| Makaida et al., “Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier”, Polymers (Basel), vol. 3, No. 3, pp. 1377-1397 (2011). |
| Julinova et al., “Initiating biodegradation of polyvinylpyrrolidone in aqueous aerobic environment”, Proceedings of ECOpole, vol. 6, No. 1, pp. 121-127 (2012). |
| Kunduru et al., “Biodegradable polymers: Medical Applications”, Encyclopedia of Polymer Science and Technology, pp. 1-22 (2016) DOI: 10.1002/0471440264.pst027.pub2. |
| Number | Date | Country | |
|---|---|---|---|
| 20140276366 A1 | Sep 2014 | US |
| Number | Date | Country | |
|---|---|---|---|
| 61801904 | Mar 2013 | US |
